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Chapter 1. Introduction 
 
Form Selection in Small Molecule Drug Development 
Small molecule drug development relies on the ability to achieve efficacious 
exposure levels of the drug with a desired dosage form.  Many active pharmaceutical 
ingredients (APIs) have poor solubility in an aqueous environment rendering them 
susceptible to solubility limited absorption.  Pharmaceutical strategies for overcoming 
absorption limited by solubility have been restricted to salt formation or formulation 
techniques such as amorphous dispersions and nanosizing or a combination thereof.1  In 
recent years cocrystallization of an API with a cocrystal former has been shown to be a 
complimentary pharmaceutical strategy to change the physical properties of the API 
including dissolution rate and solubility.2,3   
Form selection of an API in discovery research classically requires the 
comparison of two or more forms (i.e. polymorphs, salts, solvates) of the API in vivo to 
illustrate acceptable preclinical pharmacokinetics for further development of the drug.4-6  
At the outset, physical property filters such as stability, hygroscopicity and crystallinity 
of the forms are used to narrow down the field.  Predictive methods such as solubility and 
dissolution are also incorporated into the form selection decision tree to eliminate forms 
that are likely to perform poorly in vivo.7-9  The directly proportional relationship of 
dissolution rate to exposure of a poorly soluble API and its different salts, polymorphs or 
formulations has been well established and therefore remains engrained in the form 
selection process.10-14  Crystal surface properties and crystal morphology either measured 
or calculated may also be used to predict or confirm the results.15,16   
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Pharmaceutical cocrystals are molecular complexes of an API and one or more 
cocrystal formers, which are solids at room temperature, interacting through hydrogen 
bonding, π-stacking or van der Waals forces.17  Under this definition pure salts, solvates 
and hydrates are excluded although have been shown to co-exist within the same 
complex.18  In recent years interest in cocrystallization has gained momentum as noted by 
the increased frequency of occurrence of organic molecular complexes in the Cambridge 
Structural Database19.  A cursory search of the literature in 2009 alone found reports of 
novel cocrystals of APIs20-22, cocrystal screening methods23,24, cocrystal phase 
diagrams25,26, prediction of cocrystal formation27 and physicochemical properties of 
corystals3,28.  Inclusion of cocrystals in the form selection process of an API is destined to 
become, if it has not already, common practice in pharmaceutical reasearch, not only due 
to the possibility of improving physical properties of an API, but also to protect its 
intellectual property29. 
 
Introduction to AMG 517 
AMG 517, a potent and selective transient receptor potential vanilliod 1 (TRPV1) 
antagonist for the treatment of chronic pain, is an anhydrous free base form A (FBA) 
with poor aqueous solubility which is not amenable to stable salt formation due to its low 
pKa of -0.52 (ACD/pKa DB v12.0, Advanced Chemistry Development, Inc).  A second 
anhydrous form, form B (FBB), and a monohydrate (FBC) also have poor solubility in 
aqueous media which rendered them undesirable for development.30  This API has many 
known cocrystal forms, 22 of which have been published with powder dissolution data in 
FaSIF.  Almost all of the cocrystals (15/22) have shown improvements over the free form 
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based on solution concentration maximum during the dissolution experiments.31,32  One 
of these cocrystals, the sorbic acid cocrystal (SRA), has also shown improvement in the 
exposure of AMG 517 where a 30 mg/kg dose of the cocrystal was comparable to a 500 
mg/kg dose of FBA in rats when dosed as a suspension in 10% Pluronic® F108 in 
OraPlus®.30   
Further research was conducted here with sixteen cocrystals of AMG 517 to 
investigate correlations in dissolution with pharmacokinetics of cocrystal forms of a 
poorly soluble API.  The main intention of the research is to show that cocrystals with a 
higher dissolution rate than the free form will also provide higher exposure in rat 
pharmacokinetic studies.  This would allow the pharmaceutical scientist to use 
dissolution rate as a filter for selecting not only salts or polymorphs of an API, but also 
cocrystal forms for further study in vivo.  The relatively large selection was chosen to 
include SRA as a positive control, two pairs of cocrystals (carboxylic acid with 
corresponding amide) and eleven other carboxylic acid cocrystals elected to represent a 
range of dissolution rates.  With an additional hydrogen bond donor in comparison to the 
acids the amides are likely to form a unique hydrogen bonding network resulting in 
changes to the crystal packing and in turn the physicochemical properties of the 
compound.  The crystal structures of one pair of these cocrystals are analyzed in 
comparison with FBA to elucidate the possible factors responsible for changes in 
dissolution.  Single crystal structure analysis may be another useful filter in selecting API 
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Chapter 2. Cocrystal Background 
 
History of Cocrystals 
 Cocrystals have been discussed in the literature since 1844 when Wöhler first 
described quinhydrone (molecular complex of quinone and hydroquinone) and Ling 
further investigated halogen derivatives of quinhydrone in 1893.1  Cocrystals of 
antipyrine, an analgesic, were described in Modern Materia Medica published in 1895.2,3 
Some of these antipyrine cocrystals among many other cocrystals were published in 
Pfeifer’s book Organische Molekulver-bindungen (Organic Molecular Compounds) in 
1922.3,4  Around that time Kofler began publishing extensively on forming cocrystals 
through thermal microscopy techniques.3 Then, in the 1940’s McIntosh et al described a 
sulfathiazole and 3,6-diaminacridine complex which was used as an antibacterial and 
theophylline complexes with glycine or phenobarbital were described by Higgins and 
Krantz respectively.5-8  Extensive reviews on these cocrystals and many others have been 
published in the last few years by Zaworotko et al9, Schultheiss and Newman10, 
Meanwell7 and Stahly.3 
Terminology used to describe cocrystals has been diverse including phrases such 
as “molecular complexes”, “addition compounds” or “solid-state complexes” to name a 
few.9  The definition of cocrystals given in Chapter 1 is one of many proposed in the 
literature which requires the components of the crystal to be solids at ambient 
temperatures.  Other definitions are more encompassing such as the one proposed by 
Stahly “unique crystalline solids containing multiple components” where a component is 
described as “an atom, ionic compound or molecule”.3,11  This definition would also 
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incorporate hydrates, clathrates and solvates under the same umbrella.  As noted by 
Stahly, the term used to define a solid selected for development of an API is of little 
concern as long as the components are pharmaceutically acceptable from a safety 
standpoint,11 however the classification may prove to be valuable to protect the 
intellectual property of the API forms and simply removing the ambiguity that exists 
today. 
Utility of Cocrystals 
The recent popularity of cocrystals in the literature is centered on pharmaceutical 
cocrystals, but there are many other areas where cocrystals (in the broader sense) have 
been identified which were covered in detail in the 2009 perspective by Staley3 including 
the adenine:thymine and guanine:cytosine base pairs in DNA, nucleotides and 
aminocarboxylic acids cocrystallized in sun screens, hair dyes containing polyhydric 
phenols and aromatic diamines and urea: sugar cocrystals for finishing of fabric in the 
textile industry.  Purification with cocrystals was also described by Stahly3 where chiral 
or enantiomeric selectivity of the cocrystal was exploited.   
The spotlight in current years has been on pharmaceutical cocrystals and the 
ability to address many familiar tribulations encountered in drug development such as 
polymorph control, stability, crystallinity, dissolution rate, solubility and bioavailability.  
Two examples of polymorph control in the literature are cocrystals of the 
pharmaceuticals caffeine and piracetam.  Selective crystallization of two polymorphs of a 
caffeine and glutaric acid cocrystal were conducted through grinding techniques.12  
Grinding of caffeine and glutaric acid in a grinding jar with four drops of a non-polar 
solvent or no solvent resulted primarily in cocrystal form I. When polar solvents were 
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added in place of the non-polar solvents cocrystal form II was the prevalent form.  In a 
similar study the polymorphic drug piracetam was cocrystallized with two polymorphic 
cocrystal formers, gentisic acid or p-hydroxybenzoic acid by slow evaporation from 
acetonitrile.13  These cocrystals were then produced via solvent drop grinding with 23 
different solvents or by slurry in water.  Neither piracetam cocrystal exhibited 
polymorphism in these studies.   
Theophylline and caffeine are two structurally similar pharmaceutical compounds 
which are susceptible to conversion between anhydrate and hydrate as a function of 
relative humidity (RH).  Investigations were conducted by Trask, Motherwell and Jones 
to form cocrystals of these compounds with the intent of stabilizing the drugs to humidity 
changes.14,15  In both cases multiple anhydrous cocrystals were formed and one (oxalic 
acid cocrystal in both cases) was found to be stable from 0-98% RH throughout the time 
frame tested of 7 weeks. 
Co-crystalization of an API with a cocrystal former has been demonstrated to be a 
successful method for altering the dissolution rate of an API as covered in recent 
reviews.7,9,10  Improvements to the dissolution of the API of interest were found for the 
drugs indomethacin, fluoxetine and itraconazole.  The indomethacin cocrystal with 
saccharin was found to dissolve instantaneously in 60 or 200 mM phosphate buffer at pH 
7.4 reaching solution concentrations of ~3.0-3.7 mg/mL as compared to the γ-form of 
indomethacin which required 250 min to reach a lower maximum solution concentration 
of 0.72 – 1.3 mg/mL in the two buffers respectively.16  Fluoxetine hydrochloride 
cocrystallized with benzoic acid, succinic acid or fumaric acid presented variable 
behavior in intrinsic dissolution studies where two of the cocrystals dissolved more 
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slowly than the API alone while the third cocrystal (succinic acid) displayed a faster 
dissolution rate than the API in water.17  Itraconazole, an insoluble antifungal drug, is 
marketed as in the amorphous form to attain oral bioavailability.  Three cocrystals of 
itraconazole were compared to crystalline and amorphous forms of the free API in a 
dissolution study in 0.1N HCl.18  All three cocrystals were superior to the crystalline 
itraconazole and the malic acid cocrystal was found to behave similarly to the marketed 
form. 
Few examples exist in the literature where dissolution of the cocrystal is 
correlated with exposure.  Theophylline tablets from different manufacturers were 
suspected to perform differently in the clinic partially due to complexation of the 
theophylline with phenobarbital during tablet processing.19    Dissolution studies of 
theophylline and the theophylline-phenobarbital complex were conducted in water, 
0.02% polysorbate 80 and simulated gastric fluid.  In all media the complex slowed the 
dissolution of theophylline.  This correlated well to the pharmacokinetics in humans 
where seven of nine subjects produced high serum levels of theophylline quicker when 
dosed with theophylline alone than when dosed with the complex.  One subject was also 
dosed with a physical mixture of theophylline and phenobarbital which performed 
similarly to theophylline alone indicating that any pharmacodynamic properties of 
phenobarbital were not responsible for the decrease.19  A sodium channel blocker with 
low solubility when co-crystallized with glutaric acid was shown to have an intrinsic 
dissolution rate in water 18 times that of the free base. When dosed as neat solids in a 
gelatin capsule at 5 and 50 mg/kg to dogs a 3 fold improvement of AUC was achieved at 
both dose levels with the cocrystal.20  The poorly soluble anti-epileptic agent 
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carbamazepine co-crystallized with  saccharin was shown to be a feasible option, in terms 
of exposure in dogs, to the marketed Tegretol® tablets which contain an anhydrous 
polymorph of carbamazepine.21  The cocrystal, dosed as a blend with lactose in an HPMC 
capsule at 200 mg (carbamazepine equivalents), maintained consistently higher exposure 
levels than the Tegretol® tablet however the pharmacokinetic parameters were not found 
to be statistically different.  In a separate study L-883555, a phosphodiesterase IV 
inhibitor with poor bioavailability, was cocrystallized with L-tartaric acid.  The cocrystal 
improved the aqueous solubility of the free base from 7.5 to 23.7 μg/mL which 
corresponded to improved plasma concentrations from a 3 mg/kg dose in rhesus monkey 
achieving an AUC (μg/mL*h) 0.24 for the free base and 5.5 for the cocrystal.22  In a 
recent investigation into the dissolution and bioavailability of lamotrigine crystal forms a 
10 mg/kg dose in rats formulated as a suspension in 5% polyethylene glycol 400 and 95% 
methyl cellulose aqueous solution resulted in lower exposures for two lamotrigine 
nicotinamide cocrystals (anhydrous and monohydrate forms) compared to the pure drug 
(AUC0-24h 37, 26 and 60 μg/mL respectively).23  The drug concentrations over time in 
water or at pH 1 do not appear to correlate with the AUC.  In water the anhydrous 
cocrystal achieves a higher solubility than the pure drug while at pH 1 both cocrystals 
maintain a higher concentration than the pure drug. 
 
Conclusions 
 Regardless of terminology or definition, cocrystals have been investigated since 
the 1840’s for various functionalities across industries.  The interest has been amplified 
over recent years in the pharmaceutical industry as more literature is produced 
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exemplifying the ability to overcome physical property liabilities in an API.  Cocrystal 
screening will likely become (if it is not already) as inherent a pharmaceutical technique 
as salt screening in the search for developable forms of a novel API. 
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Chapter 3. Preparation and Characterization of AMG 517 Cocrystals 
 
Introduction 
Cocrystals have been produced through a variety of different methods including 
grinding of dry components alone or with a drop of solvent in a mortar and pestle or 
ballmill, crystallization from the melt of the components, moisture generated cocrystals 
as well as the more traditional crystallization techniques such as solution or slurry 
crystallizations.1-7  All of these techniques have their benefits and drawbacks such as 
small material requirements for cocrystal screening, scalability of the process for 
manufacture of drug substance, polymorph control and “green” chemistry reducing 
solvent usage.1,6  Although there are a variety of cocrystallization methods available to 
the pharmaceutical scientist all processes may not be successful at producing a particular 
cocrystal of interest, therefore it is useful when screening for new crystal forms to utilize 
multiple techniques. 
Characterization of cocrystals has been similar to that of a salt or solvate of an 
active pharmaceutical ingredient (API).  Initially, the crystal form was determined to be 
distinctive from that of the starting crystal form (and not simply a mixture of the two 
starting materials) by a variety of available methods such as X-ray powder diffraction 
(XRPD), thermal gravimetric analysis (TGA), differential scanning calorimetry (DSC) or 
Raman spectroscopy.  Once the uniqueness of the crystal form was confirmed analytical 
methods such as nuclear magnetic resonance (NMR) or high pressure liquid 
chromatography coupled with ultraviolet (HPLC-UV) or mass spectroscopy (LC-MS) 
should be utilized to determine that the API and cocrystal former are both present in the 
new material and that neither has degraded into a new molecule.  Distinguishing a 
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complex as a salt or a cocrystal has been defined by calculating differences in pKa values 
(ΔpKa) between the acid and base in the complex.  In the case of a basic drug the pKa of 
the drug minus the pKa of the acid cocrystal former resulting in a ΔpKa < 0 is said to 
result in a cocrystal and ΔpKa > 3 in a salt.8  The area between ΔpKa of 0 and 3 however 
requires a secondary technique to determine if proton transfer has occurred.  Single 
crystal structure determination and solid state NMR are two techniques that have been 
used in this capacity.9,10 
Single crystal structure analysis has been applied broadly within the 
pharmaceutical industry.  Crystal structures of APIs are frequently determined in 
pharmaceutical research to confirm the molecular structure of a single molecule.  
Complexes, such as hydrates, solvates and salts or combinations thereof may also be 
confirmed by solving the single crystal structure.  Determining the location of the guest 
molecule within the crystal lattice of a complex, i.e. in a channel or occupying a specific 
site within the crystal, and how they bind to the API can elucidate issues with physical 
and chemical stability and possibly provide insight on how to improve the form.  When it 
comes to cocrystals, crystal engineering has utilized crystal structure analysis to identify 
common hydrogen bonding synthons that can be exploited to design new crystal forms of 
an API.11-13  Single crystal structures have also been used to distinguishing between a salt 
and cocrystal.  When carboxylic acids are involved, the distances of the C-O bonds in the 
carboxylic acid in the single crystal structure have been measured.  A neutral carboxyl 
group will have two distinctively different distances (ΔDC-O >0.08) where the carboxyl 
anion will have two similar distances (ΔDC-O < 0.03).8  
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Cocrystals of AMG 517 were prepared here through tradition solution or slurry 
crystallizations to produce the bulk powders.  These powders were than characterized by 
XRPD, TGA, DSC, HPLC-UV, laser diffraction, microscopy and 1H NMR to confirm 
their identity, purity, potency, crystallinity and particle size.  Single crystals were also 
grown from solution crystallization methods including vapor diffusion, evaporation and 
slow cooling procedures.  Crystal structures were determined and analyzed to confirm 
that the complexes were cocrystals rather than salts and to explore the hydrogen bonding 
heterosynthons.  The structures of AMG 517 and the cocrystal formers selected for 
investigation are shown in figure 3.1 along with a letter designation which will be used to 
identify each compound, after its first mention here, for clarity throughout this 
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Figure 3.1. Chemical structures of FBA) AMG 517 free base, ADA) adipic acid, BZA) 
benzoic acid, BZD) benzamide, CNA) trans-cinnamic acid, CND) cinnamamide, HBA) 
2,5-dihydroxybenzoic, GUA) glutaric acid, GYA) glycolic acid, HXA) trans-2-hexanoic 
acid, HCA) 2-hydroxycaproic acid, LCA) L(+)-lactic acid, MEA) maleic acid, MIA) L-






X-Ray Powder Diffractometry 
X-ray diffraction (XRPD) patterns were obtained on a PANalytical X’Pert PRO 
X-ray diffraction system (Almelo, the Netherlands).  Samples were scanned in 
continuous mode from 5-45 º (2θ) with step size of 0.0334 º on a spinning stage at 45 kV 
and 40 mA with CuKα radiation (1.54 Å).  The incident beam path was equipped with a 
0.02 rad soller slit, 15mm mask, 4 º fixed anti-scatter slit and a programmable divergence 
slit.  The diffracted beam was equipped with a 0.02 rad soller slit, programmable anti-
scatter slit and a 0.02 mm nickel filter.  Detection was accomplished with an RTMS 
detector (X’Celerator).  Data analysis was conducted with PANalytical X’Pert Data 
Viewer software. 
Thermal Analysis 
Differential scanning calorimetry was performed on a TA Instruments Q100 
calorimeter (New Castle, DE) at 10 ºC/min from 30 to 300 ºC in an open, aluminum pan.  
Thermal gravimetric analysis was performed on a TA Instruments Q500 analyzer at 10 
ºC/min from 30 to 300 ºC in a platinum pan.  Data analysis was accomplished with TA 
Instruments Universal Analysis 2000 software v4.4A. 
Proton Nuclear Magnetic Resonance 
1H Nuclear Magnetic Resonance analysis was performed on a Bruker 400 MHz 
NMR (Germany) in DMSO-d6 at 25 ºC.  Data analysis conducted with 
ACD/SpecManager software v12.01 (Toronto, Canada). 
High Pressure Liquid Chromatography 
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HPLC-UV was performed on an Agilent 1100 series HPLC (Palo Alto, CA) 
equipped with a binary pump (G1312A), DAD detector (G1315B), auto sampler 
(G1329A) and a 4.5 x 150 mm, 8 nm pore size, 5μm particle size, Eclipse XDB C18 
column.  Elution was achieved by a gradient method from 10 to 95% of solvent B (98% 
acetonitrile, 2% water, 0.1% triflouroacetic acid) in solvent A (98% water, 2% 
acetonitrile, 0.1% triflouracetic acid) at 1 mL/min for 8.0 min, isocratic 8.0 to 10.0 min 
then equilibrate at 10% solvent B 10.5 – 15.0 min.  AMG 517 standards were prepared in 
methanol at 0.05 mg/mL and injected at 0.5, 1, 5, 10 and 15 μL (R2 1.000).  Detection 
was accomplished at 280 nm.  Data analysis was conducted with Dionex Corporation 
Chromeleon Client v6.8 (Sunnyvale, CA) software.   
Particle Size Analysis 
Particle size of dry powders was determined by laser diffraction on the Sympatec 
HELOS/BF with a RODOS/M disperser equipped with the ASPIROS powder feeder 
(Clausthal-Zellerfeld).    The powder (10-50mg) was delivered at 50 mm/s with a primary 
pressure of 1 bar and analyzed for 2 s on the R1 or R3 lens in triplicate. 
Microscopy 
Polarized light microscopy photomicrographs were acquired on a Nikon Eclipse 
E600 POL microscope (Melville, NY) at 200x magnification with a Nikon Digital Sight 
DS-5M camera and Media Cybernetics Image Pro Plus v5.1 (Bethesda, MD) software. 
Bulk Powder: Crystallization Methods 
Drug substances, AMG 517 free base form A (FBA) and the AMG 517 sorbic 
acid cocrsytal (SRA) were synthesized by Amgen, Inc.14,15  The AMG 517 adipic acid 
(ADA), AMG 517 benzoic acid (BZA), AMG 517 benzamide (BZD), AMG 517 trans-
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cinnamic acid (CNA), AMG 517 cinnamamide (CND), AMG 517 2,5-dihydroxybenzoic 
acid (HBA), AMG 517 glutaric acid (GUA), AMG 517 glycolic acid (GYA), AMG 517 
trans-2-hexanoic acid (HXA), AMG 517 2-hydroxycaproic acid (HCA), AMG 517 L(+)-
lactic acid (LCA), AMG 517 maleic acid (MEA), AMG 517 L-malic acid (MIA), AMG 
517 malonic acid (MOA) and AMG 517 succinic acid (SCA) cocrystals were prepared 
by slurry or solution crystallization.  FBA (1.0 g - 3.2 g) and the cocrystal former (0.2 g - 
2.0 g) were weighed into a 50 mL glass vial in a 1:1 or 2:1 molar ratio (FBA to former).  
Ethyl acetate (15-46 mL) was then added and stirred at 50 – 55 ºC for 1hr.  Solutions 
were allowed to cool to room temperature.  Slurries or precipitate from cooled solutions 
were isolated by filtration through a 0.22μm nylon membrane filter and air dried for 24hr.   
Single Crystal: Crystallization Methods 
 ADA: FBA was dissolved at 10.0 mg/mL in ethyl acetate at room temperature.  A 
10.0 mg/mL suspension of adipic acid in ethyl acetate was prepared at room temperature.   
The FBA solution and the adipic acid suspension were filtered through 0.22 μm nylon 
syringe filters into separate clean glass vials.  The two filtrates were mixed 1:1 into a new 
clean glass vial, capped and left at room temperature. 
  BZA: FBA was dissolved at 10.0 mg/mL in ethyl acetate at room temperature.  
Benzoic acid was dissolved at 8.6 mg/mL in ethyl acetate at room temperature.   The 
FBA and benzoic acid solutions were filtered through 0.22 μm nylon syringe filters into 
separate clean glass vials.  The two filtrates were mixed 1:1 into a plastic eppendorf tube, 
capped stored at 50 ºC. 
 CND: A solution of cocrystal CND (21.8 mg in 2 mL) in ethyl acetate was 
prepared.  The solution was filtered through a 0.22 μm nylon syringe filter into a clean 
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glass vial.  An aliquot (0.5 mL) of this solution was added to a 1 mL glass tube which 
was placed inside an 8.0 mL glass vial containing 1mL hexane.  The 8.0 mL vial was 
capped and left at room temperature. 
GUA: A solution of cocrystal GUA (22.6 mg in 2 mL) in ethyl acetate was 
prepared.  The solution was filtered through a 0.22 μm nylon syringe filter into a clean 
glass vial.  An aliquot (0.5 mL) of this solution was added to a 1 mL glass tube which 
was placed inside an 8 mL glass vial containing 1mL hexane.  The 8 mL vial was capped 
and left at room temperature. 
GYA:  A solution of cocrystal GYA (6.2 mg in 1.0 mL) was prepared in butyl 
acetate saturated with polyvinylpyrrolidone (PVP) K25 in a glass vial.  The vial was 
capped and stored at 50 ºC for 3 days.  The sample was then slow cooled at 2 ºC/hr to 
room temperature, then left at room temperature. 
HCA: FBA was dissolved at 10.0 mg/mL in ethyl acetate at room temperature.  2-
Hydroxycaproic acid was dissolved at 9.0 mg/mL in ethyl acetate at room temperature.   
The FBA and 2-hydroxycaproic acid solutions were filtered through 0.22 μm nylon 
syringe filters into separate clean glass vials.  The two filtrates were mixed 1:1 into a 
clean glass vial, capped and stored at 50 ºC for 38 days at which time 1 drop of benzene 
was added, a pin hole was poked through the cap and the sample was left at room 
temperature.   
LCA: FBA was dissolved at 10.0 mg/mL in ethyl acetate at room temperature.  
L(+)-Lactic acid was dissolved at 6.2 mg/mL in ethyl acetate at room temperature.   The 
FBA and L(+)-lactic acid solutions were filtered through 0.22 μm nylon syringe filters 
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into separate clean glass vials.  The two filtrates were mixed 1:1 into a clean glass vial, 
capped and stored at room temperature.  
MEA:  A solution of cocrystal MEA (4.6 mg in 1.0 mL) was prepared in ethyl 
acetate saturated with PVP K25 in a glass vial.  The vial was capped and stored at 50 ºC 
for 3 days.  The sample was then slow cooled at 2 ºC/hr to room temperature, then left at 
room temperature. 
Single Crystal: X-Ray Structure Determination Method 
Single crystal structures for FBA, SRA, CNA and HXA were reported 
previously.15,16  Single crystal structures for all other co-crystals with suitable single 
crystals were determined by Dr. Richard J. Staples of Michigan State University and 
Crystallographic Resources Inc. (Dewitt, MI).  Data were collected using a Bruker CCD 
(charge coupled device) based diffractometer equipped with an Oxford Cryostream low-
temperature apparatus operating at 173 K. Data were measured using omega and phi 
scans of 0.5° per frame for 30 s. The total number of images was based on results from 
the program COSMO1 where redundancy was expected to be 4.0 and completeness to 
100% out to 0.83 Å. Cell parameters were retrieved using APEX II software and refined 
using SAINT on all observed reflections. Data reduction was performed using the SAINT 
software which corrects for Lp. Scaling and absorption corrections were applied using 
SADABS multi-scan technique, supplied by George Sheldrick. The structures are solved 
by the direct method using the SHELXS-97 program and refined by least squares method 




Results and Discussion 
 
Preparation and Solid State Characterization 
Fifteen cocrystals were successfully prepared through solution or slurry 
crystallization techniques.  A total of 29 crystallizations of approximately 1-2.5 g scale 
were conducted to produce 1-2 g per cocrystal (table 3.1).  Crystallization conditions 
were not optimized and therefore low yields were encountered in some cases requiring 2-
3 batches to be combined to reach the target amount.  The desired powders were then 
hand ground in a mortar and pestle to reduce particle size and blend multiple 
crystallizations into one homogeneous batch.  Particle size reduction was conducted in 
order to harmonize the mean particle size of the cocrystals with the FBA and SRA 
material available in house which had already been micronized.  Mortar and pestle hand 
grinding technique was chosen over other available methods such as ball milling and jet 
milling because it produces less mechanical stress.  Mechanical stress can introduce 
defects to the crystal faces, produce amorphous content or other changes to the solid form 
which may influence the dissolution of the powder18,19.   
 
 23
Table 3.1. Summary of crystallization conditions to produce each cocrystal 
 
Cocrystal 





(mL) Sol/Slurry Evaporation 
Recovery 
(mg) 
ADA 1024 350 15 Slurry NO 1004 
ADA 1293 224 18 Slurry NO 1074 
BZD 2579 730 26 Slurry NO 1594 
BZA 1003 283 40 Slurry NO 926 
BZA 1424 403 46 Slurry NO 1172 
CND 2548 860 26 Slurry NO 2152 
CNA 1035 362 40 Slurry NO 1012 
CNA 1251 441 40 Slurry NO 1299 
HBA 1021 360 40 Slurry NO 871 
HBA 1452 512 40 Slurry NO 613 
HBA 1040 376 20 Slurry NO ~940 
GUA 1004 300 20 Solution YES 104 
GUA 2074 621 35 Solution NO 578 
GUA 1766 537 22 Solution NO ~780 
GYA 2126 775 21 Solution NO ~1720 
HXA 1253 346 20 Solution NO <1g 
HXA 2085 556 26 Solution NO 986 
HCA 3134 1988 43 Solution YES >2g 
LCA 2232 977 21 Solution NO 1590 
LCA 1393 640 16 Solution NO 739 
MEA 1036 327 15 Slurry NO 712 
MEA 1816 276 16 Slurry NO 791 
MEA 1044 174 16 Slurry NO ~681 
MIA 1037 282 15 Slurry NO 930 
MIA 1661 230 18 Slurry NO 1006 
MOA 1019 247 15 Slurry NO 816 
MOA 1675 397 16 Slurry NO 1341 
SCA 1045 294 15 Slurry NO 754 
SCA 2485 338 32 Slurry NO 1361 
 
Particle sizes of all powders measured by laser diffraction are listed in table 3.2.  
Mean particle sizes range from 1.73-6.24 μm (d50).  The full particle size distributions are 
located in the appendix.  All powders were analyzed by X-ray powder diffraction 
(XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), 
proton nuclear magnetic resonance (1H NMR), near-infrared spectroscopy (NIR) and 
high pressure liquid chromatography (HPLC).  All XRPD patterns (figure 3.2) and 
DSC/TGA thermograms indicate crystalline material matching the powder patterns and 
thermograms of historical data indicating that the desired form was produced.  Melting 
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onsets determined by DSC and weight loss % on TGA are listed in table 3.2 while 
complete spectral data and thermograms are compiled in the appendix.   





























































potencyd particle size (μm)
e 
compound 
base:acid (ºC) % % d10  d50  d90 
FBA NA 228 0.7 NA 0.44 1.73 4.58 
ADA 2:1 205 14.9 102.0% 0.64 2.46 7.45 
BZA 1:1 174 21.9 101.9% 0.53 1.85 6.89 
BZD 1:1 177 22.3 101.8% 0.57 2.15 7.8 
CNA 1:1 214 25.8 102.2% 0.83 4.59 22.02 
CND 1:1 184 26.0 102.2% 0.75 2.92 8.79 
HBA 2:1 226 19.0 100.0% 0.89 4.35 47.33 
GUA 1:1 149 23.8 100.0% 0.91 4.06 22.19 
GYA 1:1 137 14.1 101.5% 0.62 3.52 16.09 
HXA 1:1 128 21.0 104.0% 0.87 4.00 20.80 
HCA 1:1 133 20.5 104.2% 1.02 6.24 33.28 
LCA 1:1 118 18.1 102.3% 0.73 3.31 17.89 
MEA 2:1 192 12.3 104.0% 0.59 3.05 12.46 
MIA 2:1 218 15.8 100.3% 0.60 2.49 7.15 
MOA 1:1 186 20.0 102.4% 0.53 2.04 5.44 
SRA 1:1 159 20.8 101.3% 0.53 1.91 5.00 
SCA 2:1 206 13.3 101.2% 0.89 4.45 14.96 
(a) molar ratio of base to acid determined by 1H NMR (b) melting onset temperature 
determined by DSC (c) weight loss % due to heating determined by TGA (d) target 
potency determined by HPLC (e) particle size of original powder determined by laser 
diffraction (f) dehydration onset temperature. NA = not applicable 
 
1H NMR and HPLC were used to confirm the purity and content of the materials.  
Molar ratios of AMG 517 to cocrystal former determined by integration of the 1H NMR 
(table 3.2) were used to calculate the AMG 517 content (potency) within each cocrystal.  
Experimental potencies determined by HPLC ranged from 100 – 104% of the calculated 




Single Crystal Structures 
Crystal structures for FBA and cocrystals CNA, HXA and SRA have been 
previously reported.15,16  Crystallographic data for these and eight new crystal structures 
solved for single crystals produced during this work, ADA, BZA, CND, GUA, GYA, 
HCA, LCA and MEA are reported in table 3.3.   
 
Table 3.3. Crystallographic data of FBA and eleven cocrystals 
 
  FBA15 ADA BZA CNA16 
formula C20H13F3N4O2S C46H36F6N8O8S2 C27H19F3N4O4S C29H21F3N4O4S 
stoichiometry 1 2:1 1:1 1:1 
formula weight 430.40 1006.95 552.52 578.56 
crystal system triclinic triclinic triclinic triclinic 
space group Pī Pī Pī Pī 
a (Å) 12.861(2) 5.113(5) 4.784(3) 9.536(17) 
b (Å) 14.956(2) 15.131(5) 10.819(6) 11.326(2) 
c (Å) 11.612(3) 15.413(5) 24.403(14) 13.502(2) 
α (deg) 100.76(1) 108.414(5) 77.435(4) 65.312(3) 
β (deg) 106.00(1) 94.125(5) 88.542(4) 88.844(3) 
γ (deg) 111.387(8) 96.846(5) 82.950(4) 87.819(3) 
volume (Å3) 1893.5(5) 1115.7(12) 1223.5(12) 1324.1(4) 
calc density (g cm-3) 1.51 1.50 1.50 1.45 
Z 4 1 2 2 
T (K) 293(2) 173(2) 173(2) 193(2) 
R1 0.0540 0.1998 0.1307 0.0773 
wR2 0.0620 0.3390 0.2332 0.1170 
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  CND GUA GYA HXA16 
formula C29H22F3N5O3S C25H21F3N4O6S C22H17F3N4O5S C26H23F3N4O4S 
stoichiometry 1:1 1:1 1:1 1:1 
formula weight 577.58 562.52 506.46 544.54 
crystal system monoclinic triclinic monoclinic monoclinic 
space group C2/c Pī P 21 C2/c 
a (Å) 44.876(5) 4.629(10) 10.050(2) 62.498(18) 
b (Å) 5.102(10) 11.297(3) 5.688(2) 8.116(2) 
c (Å) 26.401(3) 24.152(7) 19.356(4) 19.870(6) 
α (deg) 90.000 89.900(2) 90.000 90.000 
β (deg) 120.012(10) 86.295(10) 97.058(2) 94.141(9) 
γ (deg) 90.000 81.042(2) 90.000 90.000 
volume (Å3) 5234.0(13) 1245.1(6) 1098.2(5) 10052(5) 
calc density (g cm-3) 1.47 1.50 1.53 1.44 
Z 8 2 2 16 
T (K) 173(2) 173(2) 173(2) 193(2) 
R1 0.0717 0.0853 0.0419 0.0903 
wR2 0.1589 0.1649 0.0954 0.0792 
  HCA LCA MEA SRA15 
formula C26H25F3N4O5S C23H19F3N4O5S C44H29F6N8O8S2 C26H21F3N4O4S 
stoichiometry 1:1 1:1 2:1 1:1 
formula weight 562.56 520.48 975.87 542.53 
crystal system triclinic triclinic triclinic triclinic 
space group Pī Pī Pī Pī 
a (Å) 4.729(11) 4.26530(10) 9.396(6) 4.720 
b (Å) 9.139(19) 10.5529(4) 13.535(8) 8.812 
c (Å) 30.731(6) 26.0208(7) 17.036(10) 29.640 
α (deg) 93.847(14) 79.685(3) 104.757(8) 89.694 
β (deg) 94.068(15) 86.626(3) 91.076(7) 85.565 
γ (deg) 98.881(14) 85.887(3) 90.354(8) 81.898 
volume (Å3) 1304.7(5) 1148.1(6) 2094(2) 1216.7 
calc density (g cm-3) 1.43 1.51 1.55 1.48 
Z 2 2 2 2 
T (K) 173(2) 173(2) 173(2) 113(2) 
R1 0.1900 0.0685 0.2087 0.0410 
wR2 0.3340 0.1544 0.2929 0.0580 
ADA This crystal was small, twined and had poor diffraction quality but confirms 
identity of the crystal17; GUA There is a 50% disorder in the acid, two orientations for 
the chain of carbon atoms17; HCA This was a very small crystal and the data is poor but 
it confirms the identity of the crystal17. Suitable single crystals of the polymorph 
representative of the powder of BZD, HBA, MIA, MOA and SCA were not obtained. 
 
Crystal structures for cocrystals BZD, HBA, MIA, MOA and SCA remain 
unavailable at this time.  Calculated powder patterns from the single crystal structures 
were confirmed to match the experimental X-ray powder pattern of the bulk powders 
used herein confirming that the single crystals are representative of the bulk powder.  The 
calculated pKa for AMG 517 (ACD/pKa DB v12.0, Advanced Chemistry Development, 
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Inc) is -0.52 while the lowest pKa of each carboxylic acids ranges from 2.39 - 4.80.  This 
results in a minimum ΔpKa of -2.91 indicating that all of the complexes are indeed 
cocrystals and not salts.  Analysis of the C-O distances in the carboxylic acids also 
confirms that the acids remain neutral with ΔDC-O values ranging from 0.09 to 0.14 
indicating that proton transfer has not occurred.   
All of the AMG 517 cocrystals with carboxylic acids reported to date hydrogen 
bond through heterosynthon 1 as illustrated by BZA in figure 3.3 where the amide proton 
on AMG 517 hydrogen bonds to the carbonyl group on the acid and the hydroxyl group 
on the acid hydrogen bonds to the benzothiozole nitrogen on AMG 517.  Of the seven 
new AMG 517 carboxylic acid cocrystal single crystal structures disclosed here five 
(ADA, BZA, GUA, HCA and LCA) also hydrogen bond through heterosynthon 1, 
though GUA also contains the common COOH--COOH homosynthon while HCA and 
LCA form chains through a hydrogen bond with the additional hydroxyl group on the 
acid and the nitrogen on the AMG 517 pyrimidine ring (figure 3.4).  It is important to 
note that cocrystals which hydrogen bond solely through this widespread heterosynthon 1 
still lead to unpredictable crystal packing (figure 3.5). 
The first reported AMG 517 carboxylic acid cocrystals which do not bind through 
heterosynthon 1 are cocrystals GYA and MEA.  The NH--O hydrogen bond of 
heterosynthon 1 for both GYA and MEA is maintained, but in MEA an intramolecular 
OH--O hydrogen bond within maleic acid and in GYA an intermolecular OH--O 
hydrogen bond between glycolic acid molecules occupies the hydroxyl group of the 
COOH.  Cocrystal GYA forms heterosynthon 2 through an OH--N hydrogen bond 
between the additional hydroxyl group on the acid and the benzothiazole nitrogen on 
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AMG 517 as shown in figure 3.4.   Based on a search of Cambridge Structural Database 
(version 5.30 with updates through Sept 2009) heterosynthon 2 is novel for multi-
component organic complexes and could be exploited in future cocrystal screening 
efforts with molecules containing similar functionalities.   
 
FBA      ADA 
       
BZA      CNA 
 
CND      GUA 
 
Figure 3.3.  Hydrogen bonding (aqua) in FBA, ADA, BZA, CNA, CND and GUA (view 
chosen to highlight hydrogen bonds; grey = carbon, blue = nitrogen, red = oxygen, 




GYA      HXA 
 
HCA      LCA 
 
MEA      SRA 
 
Figure 3.4.  Hydrogen bonding (aqua) in GYA, HXA, HCA, LCA, MEA and SRA 
(view chosen to highlight hydrogen bonds; grey = carbon, blue = nitrogen, red = oxygen, 
yellow = sulfur, green = fluorine, white = hydrogen). 
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Figure 3.5. Crystal packing diagrams of four AMG 517 cocrystals which hydrogen bond 
solely through heterosynthon 1. 
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The only amide cocrystal crystal structure CND consists of heterosynthon 3 as 
shown in figure 3.3 which consists of a hydrogen bond from the amide proton on the API 
to the carbonyl group on cinnamamide and from the amide proton on cinnamamide to the 
benzothiazole nitrogen on the API.  The additional amide proton forms a hydrogen bond 
with a neighboring cinnamamide carbonyl group forming a chain similar to that of GYA. 
 
Conclusions 
The fifteen cocrystals prepared from solution or slurry crystallization were 
determined to be crystalline, pure complexes of AMG 517 and cocrystal former in either 
a 1:1 or 2:1 molar ratio.  The X-ray powder diffraction patterns and thermal properties 
were determined to be unique to those of FBA and the mean particle sizes were all less 
then 10 μm. 
Even though the ΔpKa values were significant enough to argue that all of the 
complexes formed are cocrystals and not salts, analysis of the C-O distances in the 
carboxylic acids verifying that they are in the neutral form was still valuable information 
obtained from the single crystals structures.  The most pertinent finding from the single 
crystal structures was that the presence of both API and cocrystal former in the complex 
is confirmed as well as the molar ratio.  Also, heterosynthon 1 was seemingly robust 
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Chapter 4. Dissolution and Pharmacokinetics of AMG 517 Cocrystals 
 
Introduction 
AMG 517 was a poorly soluble small molecule drug afflicted with dissolution and 
solubility limited absorption in preclinical pharmacokinetic investigations.1  The 
traditional method to improve dissolution and solubility of an API, such as salt formation, 
proved difficult due to the low basic pKa of the molecule leading to rapid dissociation of 
salts in an aqueous environment.   Cocrystallization of AMG 517 with sorbic acid has 
been proven to improve the initial dissolution rate of AMG 517 which resulted in an 
improvement in pharmacokinetics in the rat over FBA when dosed as suspensions in 10% 
Pluronic F108 in OraPlus®.1  Further study with AMG 517 from this lab produced a 
series of AMG 517 cocrystals, most of which have been shown to improve the 
dissolution rate of AMG 517 in fasted simulated intestinal fluid (FaSIF).2,3   
Deciding which form(s) of an API to develop as the final drug substance for the 
clinic will undoubtedly include pharmacokinetic studies to ensure proper coverage of the 
drug target in vivo.4-7  Ethically the number of in vivo studies conducted has been 
minimized and therefore filters prior to pharmacokinetic investigations have been utilized 
to predict and remove from consideration forms that were likely to perform poorly in vivo 
or that were not developable due to unrelated reasons such as processability or stability.  
Dissolution rates and solubility of the API form in a biologically relevant system have 
been relied upon heavily to make this prediction due to its proven correlation for salts, 
polymorphs and formulations of a drug substance.  Cocrystals, having resurged only 
recently in the literature, do not have the same comprehensive research correlating 
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dissolution to pharmacokinetics.  Therefore the focus of this research is to analyze the 
dissolution rate and behavior of sixteen AMG 517 cocrystals and associate that to the 
exposure seen in rat pharmacokinetic studies.  Both powder and intrinsic dissolution 
methods are investigated and contrasted to one another and the fate of the remaining 




X-Ray Powder Diffractometry 
X-ray diffraction (XRPD) patterns were obtained on a PANalytical X’Pert PRO 
X-ray diffraction system (Almelo, the Netherlands).  Samples were scanned in 
continuous mode from 5-45 º (2θ) with step size of 0.0334 º on a spinning stage at 45 kV 
and 40 mA with CuKα radiation (1.54 Å).  The incident beam path was equipped with a 
0.02 rad soller slit, 15mm mask, 4 º fixed anti-scatter slit and a programmable divergence 
slit.  The diffracted beam was equipped with a 0.02 rad soller slit, programmable anti-
scatter slit and a 0.02 mm nickel filter.  Detection was accomplished with an RTMS 
detector (X’Celerator).  Data analysis was conducted with PANalytical X’Pert Data 
Viewer software. 
Thermal Analysis 
Differential scanning calorimetry was performed on a TA Instruments Q100 
calorimeter (New Castle, DE) at 10 ºC/min from 30 to 300 ºC in an open, aluminum pan.  
Thermal gravimetric analysis was performed on a TA Instruments Q500 analyzer at 10 
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ºC/min from 30 to 300 ºC in a platinum pan.  Data analysis was accomplished with TA 
Instruments Universal Analysis 2000 software v4.4A. 
Near-Infrared Spectroscopy 
NIR was performed on a FOSS NIRSystems XDSTM near-infrared rapid content 
analyzer (Laurel, MD) and the data was analyzed with Vision 3.30 software.  Absorbance 
was measured from 400 – 2500 nm.  Powders were analyzed in 20 mL clear glass 
scintillation vials with 1-2 g of compound per vial. Compacts prepared for intrinsic 
dissolution were analyzed directly pre and post dissolution.  Compacts were allowed to 
dry at room conditions for 24 hr before analysis post dissolution. 
High Pressure Liquid Chromatography 
HPLC-UV was performed on an Agilent 1100 series HPLC (Palo Alto, CA) 
equipped with a binary pump (G1312A), DAD detector (G1315B), auto sampler 
(G1329A) and a 4.5 x 150 mm, 8 nm pore size, 5μm particle size, Eclipse XDB C18 
column.  Elution was achieved by a gradient method from 10 to 95% of solvent B (98% 
acetonitrile, 2% water, 0.1% triflouroacetic acid) in solvent A (98% water, 2% 
acetonitrile, 0.1% triflouracetic acid) at 1 mL/min for 8.0 min, isocratic 8.0 to 10.0 min 
then equilibrate at 10% solvent B 10.5 – 15.0 min.  AMG 517 standards for all studies 
except intrinsic dissolution were prepared in methanol at 0.05 mg/mL and injected at 0.5, 
1, 5, 10 and 15 μL (R2 1.000).  AMG 517 standards for intrinsic dissolution were 
prepared at 1.56 μg/mL in methanol and injected at 0.1, 0.5, 1, 5 and 10 μL (R2 1.000).  
Cocrystal former standards were prepared at 0.1 mg/mL in water.  Injections were made 
at 1, 5 and 10 μL (SRA R2 0.998), or 1, 5, 10, 15 and 20 μL (BZA, BZD and HBA R2 
1.000) or 1, 5, 10 and 15 μL (CNA and CND R2 0.987).  Detection was accomplished at 
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280 nm.  Data analysis was conducted with Dionex Corporation Chromeleon Client v6.8 
(Sunnyvale, CA) software.  Representative chromatograms are shown in figure 4.1.  
Standard curves bracketed all concentration ranges for unknowns.  
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Figure 4.1. Representative HPLC-UV chromatograms of high and low standards in 
methanol and FBA in FaSIF. 
 
Particle Size Analysis 
Particle size of the suspension formulations for PK studies and the suspensions in 
FaSIF from powder dissolution studies were determined by laser diffraction on the 
Sympatec HELOS/BF with a CUVETTE disperser (Clausthal-Zellerfeld).  The 
suspension was added drop-wise to the 6mL cuvette containing 5mL vehicle (1% PVP 
K25 in water or FaSIF) until a 10-45% optical concentration was achieved.  
Measurements were taken for 10 s using R1 or R3 lens in triplicate. 
Microscopy 
Polarized light microscopy photomicrographs were acquired on a Nikon Eclipse 
E600 POL microscope (Melville, NY) at 200x magnification with a Nikon Digital Sight 
DS-5M camera and Media Cybernetics Image Pro Plus v5.1 (Bethesda, MD) software. 
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Filter Binding Investigation 
 Loss of sample due to binding to surfaces has been a common issue with 
small molecules.  Filter binding has been of significant importance especially when 
sample concentrations are very low when minute losses become significant. Due to the 
expectedly low concentrations of AMG 517 in the dissolution and formulation samples 
and investigation into the appropriate filters was conducted.  Different filter materials, 
sizes and styles were compared (table 4.1). The recovery of AMG 517 in FaSIF was best 
when a PTFE membrane was used for filtration.  Complete recovery was achieved when 
the first few drops of FaSIF were left to waste before collecting the sample.  Nylon and 
cellulose acetate recoveries were low, while the steel frit likely allowed small particles to 
pass through the filter resulting in high recoveries.  Recovery of AMG 517 from the 1% 
PVP K25 in water formulations was very low for both nylon and PTFE filters therefore 
double centrifugation (2 x 13,000 rpm for 20 min, pipette supernatant to a new vial 
before second centrifugation) was utilized as the sample preparation technique before 




Table 4.1. Summary of filter binding studies 
 
Compound Media Volume (mL) Treatment Peak Area Recovery 
FBA FaSSIF 0.5 Centrifuge 0.594 control 
FBA FaSSIF 0.5 PTFE, 0.45m, miniprep 0.590 99% 
FBA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm 0.516 87% 
FBA FaSSIF 0.5 Nylon, 0.45m, acrodisc, 13mm 0.316 53% 
FBA FaSSIF 1 Centrifuge 0.270 control 
FBA FaSSIF 1 PTFE, 0.2m, nalgene, 25mm 0.261 97% 
FBA FaSSIF 1 CA, 0.2m, whatman, 25mm 0.000 0% 
FBA FaSSIF 1 Nylon, 0.2m, acrodisc, 25mm 0.055 21% 
SRA FaSSIF 0.5 Centrifuge 5.884 control 
SRA FaSSIF 0.5 PTFE, 0.45m, miniprep 4.524 77% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm 4.536 77% 
SRA FaSSIF 0.5 Nylon, 0.45m, acrodisc, 13mm 1.497 25% 
SRA FaSSIF 1 Centrifuge 2.887 control 
SRA FaSSIF 1 PTFE, 0.2m, nalgene, 25mm 2.319 80% 
SRA FaSSIF 1 CA, 0.2m, whatman, 25mm 0.091 3% 
SRA FaSSIF 1 Nylon, 0.2m, acrodisc, 25mm 0.114 4% 
SRA FaSSIF 0.5 Centrifuge 4.651 control 
SRA FaSSIF 0.5 Steel, 0.5m, 1/8", vial 1 6.527 140% 
SRA FaSSIF 0.5 Steel, 0.5m, 1/8", vial 2 5.848 126% 
SRA FaSSIF 0.5 Steel, 0.5m, 1/8", vial 3 5.404 116% 
SRA FaSSIF 0.5 Steel, 0.5m, 1/8", vial 4 5.517 119% 
SRA FaSSIF 0.5 Steel, 0.5m, 1/8", vial 5 5.483 118% 
SRA FaSSIF 0.5 Centrifuge 7.026 control 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 1 6.993 100% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 2 7.307 104% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 3 7.321 104% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 4 7.368 105% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 5 7.374 105% 
SRA FaSSIF 0.5 Centrifuge 7.026 control 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 1* 7.216 103% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 2 7.318 104% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 3 7.311 104% 
SRA FaSSIF 0.5 PTFE, 0.45m, acrodisc, 13mm, Vial 4 7.314 104% 
SRA 1% PVP K25 0.5 Centrifuge 8.746 control 
SRA 1% PVP K25 0.5 PTFE, 0.45m, acrodisc, 13mm 0.646 7% 
SRA 1% PVP K25 0.5 Nylon, 0.45m, acrodisc, 13mm 0.917 10% 
 *Three drops of FaSIF went to waste prior to collection in vial 1. 
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Powder Dissolution Method 
 Approximately 30mg of compound was weighed into 20mL glass scintillation 
vials in triplicate.  Then, 10mL of FaSIF (5mM taurocholic acid sodium salt and 1.5 mM 
lecithin in pH 6.8 phosphate buffer) was added and continually stirred on a magnetic 
stirrer at room temperature (20-25˚C).  At each time point (1, 15, 30, 45, 60, 90, 120, 240 
and 1440 min) 0.6 mL was filtered through a 0.45 μ, 13 mm, PTFE syringe filter into an 
HPLC vial (leaving the first 4 drops to waste).  Samples were diluted 3 fold with DMSO 
to prevent precipitation if needed.  Analysis was conducted by HPLC-UV to determine 
the AMG 517 and cocrystal former (where possible) concentration in solution.  After the 
final time point the suspension was analyzed by laser diffraction and microscopy for 
particle size determination and then centrifuged 10 min at 13,000 rpm.  The surpernatent 
was discarded and the pellet was air dried for 24 hr then analyzed by XRPD, DSC and 
TGA to determine the form. 
Intrinsic Dissolution Method 
Intrinsic dissolution was conducted in a Varian VK 7025 dissolution apparatus 
(Palo Alto, CA) using a rotating disk apparatus at 37 ˚C at 100 rpm in 500 mL FaSIF for 
2 hr (n = 1) and 4 hr (n = 2). Compacts were produced by compressing 100 mg of 
compound into a die at 2000 psi (3000 psi for cocrystal HCA) for 2 min in a carver press 
(surface area 0.5 cm2).  Compacts were analyzed by NIR pre dissolution to assess form.  
FaSIF samples (0.7 mL) were withdrawn manually at each time point and filtered through 
0.45 μm PTFE syringe filter, leaving 8 drops to waste before collection into an HPLC 
vial, then analyzed by HPLC-UV at 280 nm for AMG 517 content.  Compacts were dried 
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at room temperature for at least 24 hr then analyzed by NIR and XRPD to assess the 
form. 
Dose Analysis Method 
The formulations dosed in the PK studies were analyzed pre-dose for total AMG 
517 content and pH and within 2 hr post-dose for particle size, solid form and AMG 517 
concentration in solution.  Total AMG 517 content was analyzed by HPLC-UV of a 10 
μL aliquot diluted 100x with methanol to dissolve (n=3 dilutions).  AMG 517 
concentration in solution was measured with HPLC-UV by direct injection of the 
supernatant after double centrifugation at 13,000 rpm for 20 min (n=3 injections).  The 
pellet was dried at room conditions over night then analyzed by XRPD to determine 
form. 
Pharmacokinetic Investigation Methods 
The animal procedures were conducted under a protocol approved by the Amgen, 
Inc (Cambridge, MA) Institutional Animal Care and Use Committee.  Male Sprague 
Dawley rats, 300-325 g, were obtained from Charles River Laboratories (Wilmington, 
MA) with catheters implanted in the femoral artery and vein; the surgical procedures 
were conducted under aseptic conditions.  The rats were housed in a temperature- and 
humidity-controlled environment subject to a 12 h light:12 h dark cycle and had access to 
water and a standard laboratory rodent diet ad libitum.  Animals were allowed to 
acclimate for one week prior to use.  Rats (n=3) were administered a single dose of test 
material (100 mg/kg) formulated as suspensions in 1% PVP K25 in water by oral gavage.  
Blood samples were collected from the femoral artery catheter at 0.25, 0.5 1, 2, 4, 6, 8, 
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and 24 h post-dose.  Plasma was separated by centrifugation and stored at -80° C until 
analyzed.   
Plasma standards were prepared by serial dilution in male Sprague-Dawley rat 
plasma with K2EDTA (Bioreclamation) at 25,000, 12,500, 6,250, 3,125, 1,562, 781, 391, 
195 and 98 ng/mL AMG 517.  Plasma standards and samples were extracted with a 4x 
dilution of an internal standard (ISTD) solution (acetonitrile with 0.1 % formic acid and 
200 ng/mL AMG 8316643) and centrifuged for 20 min at 4 ˚C.   
LC/MS-MS analysis of plasma extracts was conducted on an Agilent HPLC-MSD 
Trap equipped with an APCI probe, Varian Pursuit C18, 30 x 2 mm, 5 μ column and 
ChemStation software in multiple reaction monitoring (431.1 m/z and 445.1 m/z) mode.  
The chromatographic method was isocratic at 45 % acetonitrile in water with 0.1% 
formic acid at 0.75 mL/min.  Integration of the smoothed, extracted ion chromatogram at 
389.1 m/z was used for quantitation against the standard curve corrected with the ISTD 
concentration.  Integration of the smoothed, extracted ion chromatogram at 389.1 m/z 
with the Bruker Daltonics DataAnalysis for LC/MSD Trap software v3.3 was used for 
quantitation against the standard curve corrected with the ISTD concentration.  Retention 
























































Figure 4.2.  Representative mass spectroscopy chromatograms; low standard in plasma 
matrix and blank matrix (top), high standard and low standard in plasma matrix (bottom). 
 
According to the U.S Department of Health and Human Services Food and Drug 
Administration (FDA) accuracy of a bioanalytical method should be measured with a 
minimum of three concentrations and five determinations per concentration.8  The mean 
value should be within 15% of the target concentration except at the lower limit of 
quantification (LLOQ) where 20% is acceptable.  Due to the wide concentration range a 
second order polynomial regression equation and 1/x weighting was used to fit the curve.  
The goodness of fit (R2) ranges from 0.9945 – 0.9976.  With this method the mean 
accuracy of the nine concentrations which make up the standard curve, which were each 
freshly prepared and injected on eight different days, ranges from 93 – 106%.  The FDA 
guidance also suggests that the lowest standard on the calibration curve is acceptable as 
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the LLOQ if the analyte response is at least 5 times that of the blank and should be 
accurate within 80 – 120%.  The mean response of the 97.7 ng/mL standard and the mean 
response of the time zero plasma samples from each animal across all days are 334302 
and 16523 peak areas respectively.  The 97.7 ng/mL standard has a 20 times higher 
response than the blank response and a mean accuracy of 93% qualifying it as the LLOQ.  
All samples (mean of n = 3 injections) lie within the range of the standard curve and the 
lowest sample concentration (291 ng/mL) is 3.0 times higher than the LLOQ.  
Statistical Calculation Methods 
Statistical differences between groups were calculated using SigmaStat for 
Windows version 3.0.1 (SPSS Inc., Chicago, IL) applying a Kruskal-Wallis9 one-way 
analysis of variance on ranks (ANOVA) followed by a multiple comparison procedure 
versus FBA (Holm-Sidak method, p value must be lower than the critical value to be 
considered significant).  Student’s t-test was used to determine statistical significance 
between two groups. 
 
Results and Discussion 
 
Powder Dissolution 
 The powder dissolution profiles of FBA and the sixteen cocrystals in FaSIF at 
room temperature have been reported previously from this laboratory.2,3  The studies 
were repeated here to eliminate any variation between lots of compound, especially due 
to the large differences in particle size (historical data was produced with lots containing 
30-640 μm mean particle sizes).  FaSIF, besides being representative of in vivo 
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conditions10, was chosen over pure water or gastric media due to the low solubility of 
AMG 517 in water and its instability at low pH.  The powder dissolution profiles for all 
compounds are shown in figure 4.3 and associated data to be discussed below is 
summarized in table 4.2.  The dissolution profiles of the cocrystals are typical of an API 
that was not in its most stable form under these conditions and therefore crystallizes to a 
more stable form producing a decrease in solubility over time (i.e. dissociation of a salt to 
free form, amorphous to crystalline material or anhydrous to hydrate conformation).  The 
remaining solids for all compounds after 24 hr were isolated and analyzed by XRPD, 
DSC, TGA and laser diffraction to determine if any form changes occurred (example 
figure 4.4, all others appendix).  No form alteration or change in particle size of FBA was 
detected while the cocrystals all show total (HBA, GUA, GYA, HXA, HCA, LCA, 
MEA, MIA, MOA, and SCA) or partial (ADA, BZA, BZD, CNA, CND and SRA) 
crystallization to either FBA, AMG 517 free base form B (FBB), AMG 517 free base 
hydrate form C (FBC) or a mixture as well as an increased mean particle size 1.4 – 2.9x.  
A rough estimate of the % conversion of the solids from cocrystal to free form was made 
from the weight loss on TGA associated with the melt of the cocrystal and coinciding 
release of the cocrystal former.  By this technique cocrystals ADA, BZA, BZD, CNA, 
CND and SRA maintained approximately 38, 20, 35, 82, 87 and 65% of the cocrystal 



















































































































Figure 4.3.  Powder dissolution profiles to 240min of FBA and the cocrystals.  FBA is 
represented in each graph for reference.
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15 minc initial form 
 d50 (μm) d50 (μm) (μg/mL) 
final formd 
FBA 1.73 1.85 ± 0.02 3.5 ± 1.6 FBA 
ADA 2.46 7.84 ± 0.11 24.6 ± 2.0 ~38% ADA, FBB/FBC 
BZA 1.85 7.44 ± 0.90 26.4 ± 1.2 ~20% BZA, FBB/FBC 
BZD 2.15 5.94 ± 0.68 30.1 ± 0.9 ~35% BZD, FBB/FBC 
CNA 4.59 5.35 ± 0.05 11.8 ± 0.6 ~82% CNA, FBB 
CND 2.92 3.92 ± 0.00 25.1 ± 0.8 ~87% CND, FBB 
HBA 4.35 12.83 ± 0.11 17.2 ± 0.2 FBB/FBC 
GUA 4.06 7.73 ± 0.12 35.8 ± 4.0 FBC 
GYA 3.52 5.30 ± 0.12 34.3 ± 3.6 FBC 
HXA 4.00 10.26 ± 0.04 38.2 ± 2.0 FBC 
HCA 6.24 4.02 ± 0.05 18.1 ± 2.5 FBC/FBA 
LCA 3.31 4.98 ± 0.12 25.4 ± 4.4 FBC 
MEA 3.05 6.06 ± 0.01 18.7 ± 2.6 FBB/FBC 
MIA 2.49 5.99 ± 0.03 33.7 ± 2.3 FBB/FBC 
MOA 2.04 5.10 ± 0.15 36.8 ± 4.6 FBB/FBC 
SRA 1.91 1.99 ± 0.02 23.5 ± 1.0 ~65% SRA, FBB 
SCA 4.45 6.37 ± 0.02 28.1 ± 6.3 FBB/FBC 
Control FBA 1.73 1.85 ± 0.02 1.7 ± 0.5 FBA 
(a) Mean particle size of dry powder, (b) mean particle size of solids in suspension after 
24hr in FaSIF (c) concentration of AMG 517 in solution in FaSIF at 15 min and (d) solid 
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Figure 4.4. XRPD (left), DSC and TGA (right) of BZA pre and post powder dissolution. 
 
Another possible measurement of conversion to free form from cocrystal is the 
concentration of cocrystal former found in solution in the FaSIF assuming the former is 
freely soluble in the dissolution media. Based on published solubility in water of  benzoic 
acid, benzamide, cinnamic acid, cinnamamide, 2-hydroxybenzoic acid and sorbic acid 
(2.911, 13.511, 0.511, 1.312, 5.011 and 2.511 mg/mL respectively) and the amount of these 
cocrystal formers present in the powder dissolution study (0.45 – 0.76 mg/mL) all of the 
cocrystal formers would likely be completely solubilized in FaSIF with the exception of 
cinnamic acid which would be about 67% solubilized. Figure 4.5 shows the concentration 
of formers in solution during the same experiment as measured by HPLC through 240 
min for clarity.  Adipic acid was not detectable by the HPLC method utilized and is 
therefore not included in this analysis.  After 24 hr the concentration of former for 
cocrystals BZA, BZD, CNA, CND, HBA and SRA was 616 ± 20, 421 ± 27, 182 ± 19, 
120 ± 8, 423 ± 36 and 467 ± 49 μg/mL respectively.  This indicates approximately 7, 36, 
76, 84, 7 and 24% of the total former added to the dissolution experiment in cocrystal 
form is not in solution presumably remaining as part of the cocrystal.  There is good 
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agreement between the TGA and HPLC determination of % cocrystal remaining for BZD 
(35% and 36% respectively), CNA (82% and 76%), CND (87% and 84%) and HBA (0% 
and 7%) however BZA (20% and 7%) and SRA (65% and 24%) do not agree.  During 
the dissolution experiment solids are removed due to sampling (both inside and outside of 
the syringe) which decreases the amount of cocrystal or converted free base form within 
the dissolution experiment to an unknown degree.  This may account for the variability 


































Figure 4.5.  Cocrystal former solution concentrations in FaSIF over time 
 
Due to the unexpected crystallization of FBB rather than FBA in the dissolution 
experiment a brief side discussion of the relationship between these free forms seems 
necessary.  The free forms FBB and FBC, when tested under the same powder 
dissolution conditions as FBA, maintain FaSIF solubility lower than that of FBA even up 
































Figure 4.6. AMG 517 solution concentration in FaSIF over ten days. 
 
Also, FBA and FBB samples remain their original solid form as determined by XRPD of 
the isolated solids.  FBC, which appears to be a mixture of FBC and FBB to start, 
converts purely to FBC after 10 days in FaSIF (see appendix for XRPD spectra).  Based 
on solubility alone crystallization of the cocrystals to the least soluble forms, FBB and 
FBC, would be expected however, FBB has been shown to be the thermodynamically 
less stable form and monotropically related to FBA by slurry conversion experiments, 
van’t Hoff plot of solubility at different temperatures and modulated DSC.  Co-slurry of 
FBA and FBB in acetonitrlie at 30˚C or ethanol and toluene at 30˚C and 50˚C all 
crystallize to FBA.  Surry of FBB alone at 30, 40 and 50˚C in toluene also crystallized to 
FBA.  Solubility of the two forms in toluene plotted against 1/T results in parallel lines 
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Figure 4.7. van’t Hoff plot of FBA and FBB solubility in toluene. 
 
On DSC FBC dehydrates and then recrystallizes to FBB when heated to ~175˚C.  FBB 
has a broad melt and recrystallization (185-191˚C) to FBA which melts at 228˚C on 
DSC.  Modulated DSC was used to determine the heat of fusion of FBA (110 J/g) and 
FBB (3 J/g).  Based on the definition of a monotropic system the less soluble form on the 
van’t Hoff plot when lines are parallel and the form on DSC with both the highest melt 
and heat of fusion is the stable form at all temperatures.13  FBA should be more stable 
than FBB at all temperatures as determined by these methods, however in FaSIF at room 
temperature FBB did not convert to FBA after ten days and the cocrystals tend to 
crystallize to FBB or FBC rather than FBA.   Based on the Ostwald Rule of Stages the 
appearance of the thermodynamically less stable form from solution would be expected 
to appear first, however recrystallization to the thermodynamically stable form should 
follow.14  The crystallization of FBB was likely a kinetic event and presents an 
interesting twist to the interpretation of the pharmacokinetic data as there is no way of 
knowing if the same occurs in vivo in the study design used here.  Further study utilizing 
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techniques to measure real time transformation of the phases in a variety of media or a 
flow through dissolution system may provide more insight as to why FBB is present and 
if this is what occurs in vivo. 
A linear regression analysis to determine the slope of the initial dissolution rate 
proved ineffective due to the limited number of data points (2-3) before the Cmax is 
reached, therefore the concentration of AMG 517 in solution at 15 min is utilized as a 
point of comparison.  All of the cocrystals provide an increase in dissolution ranging 
from 3.4-11.0 fold over the free base (table 4.2).  This increase is statistically significant 
for all cocrystals (p < 0.001).  Cocrystals BZD, GUA, GYA, HXA, MOA and MIA 
rapidly approach and maintain a high concentration of AMG 517 from 15-45 min while 
the other cocrystals are either slow to reach a similar Cmax (ADA, BZA, CND, HCA, 
LCA, MEA, SRA, SCA) or maintain a low Cmax throughout the 24 h experiment (CNA, 
HBA).  After 4 hr the AMG 517 solution concentration is similar for all samples (6 - 13 
μg/mL) including FBA at 8 μg/mL, however after 24 hr FBA continues to dissolve 
reaching 19 μg/mL while the cocrystals remain at 5-11 μg/mL (with the exception of 
HCA at 16 μg/mL which is the only cocrystal to show evidence of crystallization to FBA 
form). 
 To ensure that the improved dissolution was due to the complex and not simply 
due to the presence of the carboxylic acid or amide a single control experiment was 
conducted.  A side by side dissolution study with the free base in FaSIF or in FaSIF with 
1 mg/mL sorbic acid added to the media was performed. The concentration of sorbic acid 
added to the FaSIF media was chosen to be in excess of the concentration of sorbic acid 
which would have resulted if all of the cocrystal SRA were to dissolve in the dissolution 
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experiment.  The dissolution profiles of the free base in either media were approximately 
identical (figure 4.8) indicating that the fast dissolution of cocrystal SRA is due to the 

































Figure 4.8.  AMG 517 solution concentration in FaSIF with or without sorbic acid 
additive compared to SRA. 
 
 Cocrystallization of AMG 517 with the carboxylic acids or amides resulted in a 
significant increase in the initial dissolution rate of the powders compared to FBA in 
FaSIF for all cocrystals.  Even though the increase is transient ending in lower solution 
concentrations after 24 hr as compared to FBA, the high initial solution concentrations 
may provide the desired increase in exposure in the rat pharmacokinetic studies. 
 
Intrinsic Dissolution 
As a compliment to the powder dissolution studies, intrinsic dissolution was also 
conducted in FaSIF.  Intrinsic dissolution was a more controlled study in that the 
temperature is held constant, particle size is no longer considered a major influential 
factor due to the consistent surface area of the compact when using the woods apparatus 
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and the amount of solution removed through sampling over time is accounted for in the 
calculations.  This method however may be less representative of the suspension 
formulation in vivo due to the difference in surface area.   
The amount dissolved at time t (St) was calculated as follows: 
St = (CtVt) + Dt 
where Ct is the solution concentration at time t, Vt is the total volume of FaSIF remaining 
at time t and Dt is the cumulative amount of drug removed from the system at time t.   
 
Table 4.3.  Summary of intrinsic dissolution analysis for FBA and the cocrystals. 
 
IDRa 
initial form (mg/cm2/min) final form
b 
FBA 0.0006 ± 0.0002 FBA 
ADA 0.0007 ± 0.0003 ADA 
BZA 0.0012 ± 0.0002  BZA, minor FBA 
BZD 0.0014 ± 0.0002  BZD, minor FBA 
CNA 0.0010 ± 0.0002 CNA 
CND 0.0013 ± 0.0002  CND 
HBA 0.0010 ± 0.0002 HBA 
GUA 0.0016 ± 0.0001  GUA, minor FBA 
GYA 0.0014 ± 0.0001  GYA 
HXA 0.0015 ± 0.0002  HXA 
HCA 0.0017 ± 0.0003  HCAc, minor FBA 
LCA 0.0010 ± 0.0002 LCA 
MEA 0.0013 ± 0.0001  MEA 
MIA 0.0014 ± 0.0002  MIA, minor FBA 
MOA 0.0016 ± 0.0002  MOA 
SRA 0.0011 ± 0.0003 SRA, minor FBA 
SCA 0.0011 ± 0.0003 SCA 
a) IDR determined from 0-30min if FaSIF b) analysis of the compact surface by XRPD 
and NIR post intrinsic dissolution c) differences noted in NIR of HCA post compaction, 
pre dissolution. 
 


























































































Figure 4.9. Intrinsic dissolution profiles at 60 min of FBA and the cocrystals. 
 
The intrinsic dissolution rate in mg/cm2/min (IDR) was determined from the slope of the 
linear regression line when St divided by the surface area was plotted against time t from 
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0-30min.  The IDR of FBA and the cocrystals are listed in table 4.3 and the dissolution 
profiles are shown in figure 4.9.  All cocrystals except ADA significantly (p ≤ 0.013) 
improve the IDR of FBA by 1.7 – 2.9 fold.   
The IDR is expected to correlate well with the powder dissolution data assuming 
that particle sizes between forms were similar and early time points were used to avoid 
the effects from phase transformation over time.  The graph in figure 4.10 comparing the 
two methods indicates that the correlation of the powder and intrinsic dissolution by 



















































Figure 4.10.  Correlation analysis of powder and intrinsic dissolution data 
 
Cocrystal HCA stands out as having a very high IDR, but a very low concentration in 
solution at 15 min in the powder dissolution study.  This may be partially due to the 
larger particle size of this cocrystal which would decrease the surface area exposed to the 
media in the powder dissolution study therefore slowing the initial dissolution rate.  The 
particle size would not affect the intrinsic dissolution study since the woods apparatus 
maintains a constant surface area of 0.5 cm2.  More realistically the difference between 
powder and intrinsic dissolution rates for HCA is likely due to compaction.  HCA was 
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the only cocrystal which required a higher compression pressure (3000psi instead of 
2000psi) in order to produce a smooth surface in the woods apparatus for the IDR study.  
The surface of the compacts were analyzed by NIR after compaction and compared to the 
original powder.  A clear change in form was detected by NIR of the 1901 and 2220nm 
peaks due to compaction (appendix).  This form change may have influenced the intrinsic 
dissolution rate of this cocrystal.  If HCA is removed from the correlation between the 
two dissolution methods the relationship greatly improves (R2 = 0.598) but is still not 
remarkable.  ADA also stands out in the correlation although due to a low intrinsic 
dissolution rate as compared to its behavior in the powder dissolution study.  There is no 
evidence of any phase transformations of ADA due to compaction or even post intrinsic 
dissolution by XRPD and NIR and its particle size distribution does not stand out from 
any of the other cocrystal forms as being particularly small.  Therefore any explanation of 
the inconsistency would be conjecture, although it is worth mentioning that the 
relationship between powder and intrinsic dissolution for the remaining cocrystals and 
FBA is far superior (R2 = 0.7289).  Nonetheless, the overall discrepancies between the 
two methods in general likely arose due to the dissimilarity in exposed surface area to the 
media and the kinetics of phase transformations occurring in both conditions.  
The intrinsic dissolution curves became non-linear after only ~30-60 min when a 
maximum of 0.1% of the total weight has dissolved.  Form conversion to a crystalline 
material with slower dissolution may have taken place on the surface of the compact 
causing the diminished dissolution rate.  Analysis of the compact surface post dissolution 
by XRPD and NIR indicate cocrystals BZA, BZD, GUA, MIA, MOA and SRA 
crystallize minor FBA on the surface.  FBA has a characteristic N-H combination region 
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peak at 2064 nm on NIR (appendix).  Based on the available single crystal structures this 
NH-N hydrogen bond between molecules of FBA is replaced by an OH-N hydrogen 
bond with the carboxylic acid of cocrystals BZA, GUA and SRA.  Therefore the growth 
of this characteristic peak in the analysis of the compact surfaces post dissolution 
indicates crystallization of the FBA on the surface.  Crystal structure of MIA and MOA 
were not available, however the same changes occur on NIR indicating similar 
circumstances are possible.  For the BZD cocrystal the NIR also points toward a slight 
change in the 2064 nm region although not as dramatic as the carboxylic acids.  The 
crystal structure was not available but based on the CND crystal structure (and other 
published amide cocrystals3 with AMG 517) it is likely that one of the amine protons 
forms a hydrogen bond with the benzothiazole nitrogen of AMG 517.  This slight change 
combined with characteristic peaks of FBA in the X-ray powder pattern provide evidence 
of minor FBA on the surface of this compact at the end of the dissolution study.  For all 
other cocrystals a phase change was not apparent.  Based on experience in the powder 
dissolution experiments where crystallization of free form was identified for all 
cocrystals, it was possible that form conversion was also occurring here but the extent is 
below the limits of detection for the methods utilized.  Another possible rationalization 
for the decreased dissolution rate over time was that the tests were not performed under 
sink conditions where the total volume of dissolution media should exceed that required 
to dissolve all of the test material or be continuously replenished.  In nonsink conditions 
dissolution would be slowed as the drug is not efficiently removed from the receptor 
phase.  Nonsink conditions were likely more representative of in vivo conditions in the rat 
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based on a gut volume of only 11.3mL15 and is thus a more appropriate environment for 
the in vitro testing to build a correlation. 
Similar to the powder dissolution results the intrinsic dissolution rates of all 
cocrystals (except ADA) were significantly improved over FBA.  The linear correlation 
between the two methods is only moderate.  Though, if intrinsic dissolution were the only 
method utilized to filter the cocrystals to be tested in vivo in a drug development 
paradigm (as opposed to powder dissolution), the selection would have likely been 
similar.  HCA is the only cocrystal with a high IDR that would have been eliminated 
based on slow powder dissolution, however due to the changes in form during processing 
in preparation for the intrinsic dissolution study; HCA would likely have been removed 
from further consideration at any rate.  The decision to use one or the other technique (or 






As mentioned in the introduction, FBA and SRA were previously dosed in rats 
using a formulation containing OraPlus®.   The same formulation could not be used for 
the pharmacokinetic evaluation here for multiple reasons.  OraPlus® contains sorbic acid 
as a preservative.  Therefore some of the free form (and possibly other cocrystals) will 
convert to the SRA with the existing sorbic acid in the formulation which would 
influence the exposure of the dose due to the higher dissolution rate of the SRA over the 
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FBA.  OraPlus® is also a suspension itself.  The solids in this suspension would greatly 
interfere with the interpretation of the analysis of the stability of the solid form of FBA 
and the cocrystals in the formulation.  For these main reasons a new formulation was 
desired.  A simple powder in capsule formulation was considered, but concerns about the 
poor wetability of the powders leading to very slow dissolution in vivo, reduced 
absorption and possibly undetectable levels of AMG 517 in the plasma lead to the design 
of a suspension formulation.  The suspending vehicle was designed for dual purpose; to 
stabilize the cocrystal form from conversion or changes in particle size for 24 hr (to allow 
for preparation of the dose the day before dosing) and to maintain consistent solubility 
across all compounds, if possible.  High solubility was not a goal of the formulation since 
the intent of this study was not to affect exposure through formulation, but through co-
crystallization.  Also, in order to physically stabilize the cocrystals in the suspension they 
need to have a lower solubility than the free forms in the vehicle.  
 From previous experience with SRA, a 2% Pluronic® F108 in water formulation 
stabilized the cocrystal in suspension, therefore all other cocrystals were tested in this 
vehicle at 10 mg/mL.  Seven of the cocrystals were not physically stable after only one 
hour as determined by XRPD of the isolated solids (table 4.4).  
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Table 4.4  Formulation development summary 






FBA 2% Pluronic F108 in water 6.00 8.4 stable 1hr 
ADA 2% Pluronic F108 in water 4.28 1.4 stable 1hr 
HBA 2% Pluronic F108 in water 3.17 2.2 stable 1hr 
GUA 2% Pluronic F108 in water 2.98 13.5 not stable 1hr 
GYA 2% Pluronic F108 in water 2.76 2.9 not stable 1hr 
HXA 2% Pluronic F108 in water 4.06 0.7 stable 1hr 
HCA 2% Pluronic F108 in water 2.98 12.8 not stable 1hr 
LCA 2% Pluronic F108 in water 2.83 6.5 not stable 1hr 
MEA 2% Pluronic F108 in water 2.48 3.1 not stable 1hr 
MIA 2% Pluronic F108 in water 2.90 4.0 not stable 1hr 
MOA 2% Pluronic F108 in water 2.36 2.7 not stable 1hr 
SRA 2% Pluronic F108 in water 4.38 2.3 stable 1hr 
SCA 2% Pluronic F108 in water 3.60 0.3 stable 1hr 
HCA 2% Pluronic F108 in 100mM PB pH 6.8 6.67 63.6 not stable 1hr 
HCA 1% HPMC 1% Pluronic 50mM PB pH 6.8 6.68 69.7 amorphous 1hr 
HCA 2% HPMC 1% Pluronic 20% HP-β-CD 3.99 217.5 amorphous 1hr 
HCA 2% HPMC 1% polysorbate 80 in water 2.98 95.1 not stable 1hr 
HCA 2% HPMC in water 3.35 41.4 not stable 1hr 
HCA 10% HP-β-CD in water 3.66 355.9 stable 24hr 
HCA 20% HP-β-CD in water 4.18 1132.0 stable 24hr 
HCA 1% Methylcellulose in water 3.57 5.1 stable 24hr 
HCA 0.5% MC 1% polysorbate 80 in water 2.93 85.8 not stable 1hr 
FBA 1% PVP K25 in water 4.67 7.2 stable 24 hr 
ADA 1% PVP K25 in water 4.42 3.2 stable 24 hr 
BZA 1% PVP K25 in water 4.57 1.3 stable 24 hr 
BZD 1% PVP K25 in water 4.70 3.3 stable 24 hr 
CNA 1% PVP K25 in water 4.53 0.9 stable 24 hr 
CND 1% PVP K25 in water 4.96 1.4 stable 24 hr 
HBA 1% PVP K25 in water 3.36 0.6 stable 24 hr 
GUA 1% PVP K25 in water 3.74 1.3 stable 24 hr 
GYA 1% PVP K25 in water 3.13 1.4 not stable 24 hr 
HXA 1% PVP K25 in water 4.49 1.7 stable 24 hr 
HCA 1% PVP K25 in water 3.53 1.2 stable 24 hr 
LCA 1% PVP K25 in water 3.52 1.0 stable 24 hr 
MEA 1% PVP K25 in water 3.56 1.8 stable 24 hr 
MIA 1% PVP K25 in water 3.70 1.5 stable 24 hr 
MOA 1% PVP K25 in water 3.47 1.1 stable 24 hr 
SRA 1% PVP K25 in water 4.48 1.7 stable 24 hr 
SCA 1% PVP K25 in water 3.92 1.7 stable 24 hr 
 
Solution concentrations of AMG 517 for the stable cocrystals in this vehicle ranged from 
0.3 – 2.3 μg/mL which was lower than the solution concentration of FBA at 8.4 μg/mL 
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after one hour.  Solution concentrations of the unstable cocrystals ranged from 2.7 – 13.5 
μg/mL.  Since an unknown amount of dissociation to the free form had occurred these 
values may not be directly interpreted.  Instability was also accompanied by a drop in the 
pH to below 3 indicating dissociation of the carboxylic acid into the solution.   To 
investigate if the dissociation could be slowed by maintaining the pH above 3 HCA and 
LCA were tested for stability in 2% Pluronic® F108 in 100 mM phosphate buffer pH 6.8.  
Within one hour, although the pH was stable, both cocrystals dissociated indicating that 
the drop in pH was a consequence of the physical instability rather than the cause of 
instability.   
The HCA cocrystal was then tested in a series of other vehicles containing 
hydroxypropyl methylcellulose (HPMC), methylcellulose (MC), hydroxypropyl-β-
cyclodextrin (HP-β-CD), polysorbate 80, polyvinylpyrrolidone (PVP) K25 and 
combinations thereof (table 4).  The cocrystal was found to be physically stabilized by 
10% or 20% HP-β-CD in water; however the solution concentration after 24 hr was very 
high at 0.355 and 1.132 mg/mL respectively.  HCA was also physically stable in 1% MC 
after 24 hr with a solution concentration of only 4 μg/mL although the formulation 
proved difficult to prepare due to the hydrophobicity of the powder rendering it very 
difficult to wet.  In order to improve the wetting of the powder a 0.5% MC and 1% 
polysorbate 80 in water vehicle was tested.  The powder was indeed easier to wet but 
HCA was no longer physically stable with an increased solution concentration to 77 
μg/mL.   
The vehicle 1% PVP K25 in water provided physical stability and a low solution 
concentration of HCA after 24 hr and also made it easier to wet the powder than the 1% 
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MC vehicle.  Therefore the remaining cocrystals and the FBA were then tested in this 
vehicle.  All cocrystals were found to be physically stable by XRPD for 24 hr with the 
exception of GYA which showed some minor dissociation to FBA after 24 hr.  This 
cocrystal was formulated within two hours of dosing to minimize the conversion.  
Solution concentrations after three hours of AMG 517 in the 1% PVP K25 in water 
formulations ranged from 0.6-3.3 μg/mL for the cocrystals while FBA was higher at 7.2 
μg/mL (table 4.4).  1% PVP K25 in water was therefore selected as the formulation 
vehicle for in vivo studies because it provided a formulation with physical stability, a 
narrow range of solubilities across all compounds and wettability.  
 
In Vivo Study: Formulation Preparation and Analysis 
The cocrystals and FBA were formulated as suspensions in 1% PVP K25 in water 
at 100 mg/kg (10 mg/mL) the day prior to dosing (except GLY which was prepared 
within 2 hr of dosing).  The dosing suspensions were all analyzed within 2 hr post dose to 
ensure consistency of the solids in form and particle size and to measure the solution 
concentration of AMG 517 (data summarized in table 4.5, XRPD data compiled in the 
appendix).  A few outliers were seen in the data.  Cocrystal MEA is the only formulation 
which has higher solubility than the free base in this vehicle.  This may have increased 
the plasma concentrations of this cocrystal in the animals (see discussion below) however 
no overall correlation with solution concentration of AMG 517 in the vehicle and 
exposure is seen.   
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Table 4.5.  Formulation analysis of AMG 517 and cocrystals. 
 
total conc. b sol. conc. c particle size d initial form pH a (mg/mL) (μg/mL)  d50 (μm) 
 final form 
FBA 4.3 9.7 ± 0.2 14.8 ± 0.0 1.49 ± 0.01 FBA 
ADA 4.1 11.7 ± 0.0 0.6 ± 0.1 2.55 ± 0.09 ADA 
BZA 4.0  11.0 ± 0.5 1.2 ± 0.2 1.85 ± 0.05 BZA 
BZD 4.2  10.2 ± 0.1 5.7 ± 0.3 1.96 ± 0.05 BZD 
CNA 4.2   9.9 ± 0.5 0.5 ± 0.1 7.96 ± 0.10 CNA 
CND 4.0   9.9 ± 0.1 2.4 ± 0.3 2.70 ± 0.03 CND 
HBA 3.4 10.2 ± 0.0 3.4 ± 0.0 2.52 ± 0.23 HBA 
GUA 4.1 9.6 ± 0.3 3.0 ± 0.2 3.65 ± 0.21 GUA, minor FBC 
GYA 3.3 10.0 ± 0.2 4.0 ± 0.4 3.05 ± 0.07 GYA 
HXA 4.0 9.8 ± 0.1 1.5 ± 0.2 4.20 ± 0.11 HXA 
HCA 3.5 10.3 ± 0.1 6.4 ± 0.5 4.16 ± 0.06 HCA 
LCA 3.0 9.7 ± 0.1 1.6 ± 0.5 19.95 ± 0.11 LCA, significant amorphous 
MEA 3.3 10.1 ± 0.2 24.3 ± 0.6 3.29 ± 0.01 MEA 
MIA 3.5 9.5 ± 0.2 9.3 ± 0.3 2.25 ± 0.02 MIA 
MOA 3.3 9.9 ± 0.1 4.8 ± 0.3 2.65 ± 0.03 MOA 
SRA 4.4 9.9 ± 0.1 5.8 ± 0.1 1.75 ± 0.01 SRA 
SCA 3.8 9.9 ± 0.0 0.7 ± 0.1 2.85 ± 0.03 SCA 
(a) pH measured pre-dose, (b) total concentration of AMG 517 measure pre-dose, (c) 
solution concentration of AMG 517 measured within 2 hr post dose and (d) mean particle 
size of formulation measured within 2 hr post dose. 
 
Cocrystal LCA possesses an unexpectedly large mean particle size based on the particle 
size of the starting powder.  The particle size increase is due to partial conversion of this 
cocrystal to an amorphous form, as seen by a halo and broadened peaks in the XRPD and 
loss of birefringence in polarized light microscopy, which then agglomerated in the 
formulation (see appendix).  The pH of this formulation was also low which is an 
indication that the cocrystal has partially dissociated.  The formulations were also 
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analyzed pre-dose for total AMG 517 concentration to insure that the suspensions were 
homogeneous and accurately prepared.  All formulations were within the target 
concentration of 10 mg/mL ± 10% with the exception of cocrystal ADA which was 17% 
above the target concentration (table 4.5).  Therefore the dose-normalized AUC 
(DNAUC) was used for all compounds in the data correlations to correct for the actual 
concentration of AMG 517. 
 
In Vivo Study: Results and Correlations with Dissolution 
The pharmacokinetic parameters are listed in table 4.6 and the plasma 
concentration over time curves are shown in figure 4.11.  The plasma concentrations 
measured for cocrystal SRA in this investigation are consistent with historical data when 
dosed as suspensions in 10% Pluronic® F108 in OraPlus® (Cmax 13,400 ng/mL and AUC0-
24h 320,000 ng*h/mL1) indicating that the 1% PVP K25 in water vehicle did not have a 
considerable effect on the exposure as intended.  The DNAUC is listed in table 9 for both 
0-6 hr and 0-24 hr in table 9 since groups CNA and CND both have one animal for which 
the time points after 6 or 8 hr are not available.  The linear regression analysis of the two 
DNAUC values correlates very well with R2 0.9069, the only outlier being CND whose 
DNAUC0-24 hr for two animals is high compared to its DNAUC0-6 hr for all 3 animals.  Due 
to this discrepancy, the DNAUC0-6 hr is used for statistical analysis.  All of the cocrystals 
increased the DNAUC0-6 hr 2.3 – 8.1 fold over the free base with 10 out of the 16 (BZD, 
CND, GUA, GYA, HXA, MEA, MIA, MOA, SRA and SCA) resulting in statistically 
significant increases (p ≤ 0.003).  The cocrystals also reach a higher Cmax than FBA with 
the same 10 cocrystals above as well as BZA qualify as significant increases (p ≤ 0.008). 
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Table 4.6.  Pharmacokinetic parameters of AMG 517 and cocrystals. 
 
Tmaxa Cmaxb DNAUC0-6hrc DNAUC0-24hrd Compound 
(hr) (ng/mL) (hr*ng/mL per mg/kg) (hr*ng/mL per mg/kg) 
FBA 4-6 2553 ± 875 116 ± 38 462 ± 169 
ADA 6-8 8638 ± 2257 329 ± 101 1454 ± 390 
BZA 1-4 13237 ± 5341 543 ± 213 1988 ± 799 
BZD 2 16900 ± 3995 789 ± 178 3000 ± 305 
CNA 2, 8 5270 268 ± 87 1072 
CND 8, 24 16310 623 ± 303 3369 
HBA 4-8 11404 ± 3353 485 ± 51 2100 ± 551 
GUA 2-8 16167 ± 5864 796 ± 311 2921 ± 848 
GYA 1-4 20110 ± 3525  938 ± 190 3444 ± 726 
HXA 2-8 13789 ± 4980 606 ± 179 2701 ± 762 
HCA 1-2 11618 ± 4827 514 ± 224 1897 ± 775 
LCA 2-8 7047 ± 3628 318 ± 155 1311 ± 701 
MEA 2-8 18145 ± 5000  810 ± 194 2976 ± 715 
MIA 2-8 18416 ± 7053  868 ± 272 3441 ± 1275 
MOA 2 19550 ± 6850  894 ± 238 3152 ± 670 
SRA 2 19533 ± 1305  882 ± 14 3283 ± 531 
SCA 2 16943 ± 2909 777 ± 130 2747 ± 602 
(a) Time of plasma maximum concentration, (b) plasma maximum concentration (c) dose 
normalized plasma area under the curve from 0-6 hr (d) dose normalized plasma area 


































































































As discussed in the introduction a correlation between dissolution rate and 
exposure is expected for the different forms of a poorly soluble molecule such as AMG 
517 where faster dissolution, under conditions relevant to the in vivo study, provides 
greater concentrations of drug in the plasma.  In general, this holds true here where all 
AMG 517 cocrystals had a faster IDR and a higher solution concentration at 15 min in 
FaSIF as well as a higher AUC as compared to FBA.  Nevertheless a strong overall linear 
correlation between powder or intrinsic dissolution rate and exposure was not seen (R2 
0.5065 and 0.4245 respectively).  Figure 4.12 shows the linear regression analysis of the 
two in vitro dissolution methods with the DNAUC0-6hr.  
Examining the powder dissolution relationship with DNAUC0-6hr, cocrystal MEA 
obtained one of the highest DNAUC0-6hr even though the concentration at 15min in 
solution in FaSIF was one of the lowest.  As mentioned previously this formulation was 
the only one with an AMG 517 concentration in solution higher than the free base 
formulation.  This may have provided the higher than expected exposure for this 
cocrystal.  Cocrystal LCA, which became partially amorphous and agglomerated in the 
formulation, has an unexpectedly low DNAUC0-6hr based on its behavior in the powder 
dissolution study.  The decrease in surface area due to agglomeration may have caused 
the low DNAUC0-6hr.  Deletion of this cocrystal from the correlation as well as cocrystal 
MEA discussed above results in an improved association (R2 = 0.6550).  
Examining the intrinsic dissolution relationship with DNAUC0-6hr it is seen that 
the IDR of cocrystal HCA may be exaggerated as discussed in the intrinsic dissolution 
section due to excessive compression inducing change to the form as seen by NIR.  
Elimination of this data point from the IDR and DNAUC0-6hr comparison greatly 
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improves the linear relationship (R2 = 0.5687).  Exclusion of cocrystals LCA and MEA 
as discussed in relation to the powder dissolution does not have a noteworthy effect on 



























0 100 200 300 400 500 600 700 800 900 1000


















































0 100 200 300 400 500 600 700 800 900 1000















Figure 4.12.  Correlation analysis of DNAUC with powder dissolution (top) and intrinsic 
dissolution (bottom) in FaSIF. 
 
Conclusion 
An increase in dissolution rate did lead to improved pharmacokinetics of AMG 
517 however a strong linear correlation with DNAUC0-6hr among the 16 cocrystals is not 
apparent.  Even with removing outliers based on the analysis of the formulations only a 
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moderate correlation was noted with both dissolution techniques although slightly 
improved for powder dissolution compared to intrinsic dissolution.  This was likely due 
to the similarity of the dosage form (suspension) to the powder dissolution conditions.  
Other parameters were also investigated in linear regression analysis such as the plasma 
Cmax instead of the DNAUC0-6hr or different time points in the powder dissolution profiles 
but the correlations were not greatly improved.    The lack of a strong in vitro/in vivo 
correlation was not too surprising considering the inherent variability within in vivo 
systems and the power of the study.   
What does come from that data and perhaps more relevant in a drug development 
setting is that one group of seven cocrystals were consistently high performers 
(highlighted in blue in figure 4.12) with DNAUC0-6hr ≥ 777 hr*ng/mL per mg/kg, IDR ≥ 
0.0011 mg/cm2/min and powder dissolution solution concentration ≥ 24 μg/mL at 15 
min.  If the cutoff criteria for a cocrystal to be examined in pharmacokinetic 
investigations in the rat had been set at a 30 μg/mL solution concentration at 15 min in 
FaSIF in the powder dissolution study six of the sixteen cocrystals would have continued 
into PK studies.  Three cocrystals with DNAUC0-6hr ≥ 777 hr*ng/mL per mg/kg would 
have been overlooked (MEA, SRA and SCA), one cocrystal would have performed 
poorly with a DNAUC0-6hr of only 606 hr*ng/mL per mg/kg (HXA) and five would have 
performed well as expected with DNAUC0-6hr ≥ 789 hr*ng/mL per mg/kg (BZD, GUA, 
GYA, MIA and MOA).  A similar analysis of the intrinsic dissolution data, dosing the 
top six cocrystals with IDR ≥ 0.0014 mg/cm2/min in PK studies, would have only 
encompassed four of the eight cocrystals with high DNAUC0-6hr ≥ 777 hr*ng/mL per 
mg/kg.  Most importantly, the two cocrystals with the highest exposures (GYA and 
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MOA) would have been encompassed by both filters thereby allowing for the selection 
of a single cocrystal form to be developed as a drug product. 
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Chapter 5. Acid and Amide Cocrystal Pairs 
 
Introduction 
Screening for pharmaceutical cocrystals of an API in industry is typically 
restricted to cocrystal formers which have a history of being safe for use in humans (i.e. 
listed as “generally regarded as safe” by the FDA and found in currently marketed 
products).1,2  Due to their known safety profile a product containing these cocrystal 
formers would be less time consuming and costly to develop.  This characteristically 
leads to a cocrystal screen of only carboxylic acids previously used as salt formers for 
basic APIs.  Arguments have been made that expanding beyond carboxylic acids would 
provide more variety in hydrogen bonding functional groups to interact with the API 
resulting in a higher probability of forming a cocrystal as well as more diverse 
physicochemical properties.  An amide in particular, with an additional hydrogen bond 
donor in comparison to a carboxylic acid,  is likely to form a unique hydrogen bonding 
network resulting in changes to the crystal packing and in turn the physicochemical 
properties of the compound.  A second motivation to screen for a larger variety of 
cocrystal forms is to protect the intellectual property of an API.   
Two case studies of the carboxylic acid cocrystals, BZA and CNA, and the 
corresponding amide cocrystals, BZD and CND, were examined here to see if the 
differences in crystal packing lead to varied dissolution and pharmacokinetics.  Also, the 
utility of the in silico tool of crystal structure analysis as an added layer to form selection 




Powder Dissolution Method 
 Approximately 30mg of compound was weighed into 20mL glass scintillation 
vials in triplicate.  Then, 10mL of FaSIF (5mM taurocholic acid sodium salt and 1.5 mM 
lecithin in pH 6.8 phosphate buffer) was added and continually stirred on a magnetic 
stirrer at room temperature (20-25˚C).  At each time point (1, 15, 30, 45, 60, 90, 120, 240 
and 1440 min) 0.6 mL was filtered through a 0.45 μ, 13 mm, PTFE syringe filter into an 
HPLC vial (leaving the first 4 drops to waste).  Samples were diluted 3 fold with DMSO 
to prevent precipitation if needed.  Analysis was conducted by HPLC-UV to determine 
the AMG 517 and cocrystal former (where possible) concentration in solution.  After the 
final time point the suspension was analyzed by laser diffraction and microscopy for 
particle size determination and then centrifuged 10 min at 13,000 rpm.  The surpernatent 
was discarded and the pellet was air dried for 24 hr then analyzed by XRPD, DSC and 
TGA to determine the form. 
Intrinsic Dissolution Method 
Intrinsic dissolution was conducted in a Varian VK 7025 dissolution apparatus 
(Palo Alto, CA) using a rotating disk apparatus at 37 ˚C at 100 rpm in 500 mL FaSIF for 
2 hr (n = 1) and 4 hr (n = 2). Compacts were produced by compressing 100 mg of 
compound into a die at 2000 psi (3000 psi for cocrystal HCA) for 2 min in a carver press 
(surface area 0.5 cm2).  Compacts were analyzed by NIR pre dissolution to assess form.  
FaSIF samples (0.7 mL) were withdrawn manually at each time point and filtered through 
0.45 μm PTFE syringe filter, leaving 8 drops to waste before collection into an HPLC 
vial, then analyzed by HPLC-UV at 280 nm for AMG 517 content.  Compacts were dried 
 76
at room temperature for at least 24 hr then analyzed by NIR and XRPD to assess the 
form. 
Pharmacokinetic Investigation Methods 
The animal procedures were conducted under a protocol approved by the Amgen, 
Inc (Cambridge, MA) Institutional Animal Care and Use Committee.  Male Sprague 
Dawley rats, 300-325 g, were obtained from Charles River Laboratories (Wilmington, 
MA) with catheters implanted in the femoral artery and vein; the surgical procedures 
were conducted under aseptic conditions.  The rats were housed in a temperature- and 
humidity-controlled environment subject to a 12 h light:12 h dark cycle and had access to 
water and a standard laboratory rodent diet ad libitum.  Animals were allowed to 
acclimate for one week prior to use.  Rats (n=3) were administered a single dose of test 
material (100 mg/kg) formulated as suspensions in 1% PVP K25 in water by oral gavage.  
Blood samples were collected from the femoral artery catheter at 0.25, 0.5 1, 2, 4, 6, 8, 
and 24 h post-dose.  Plasma was separated by centrifugation and stored at -80° C until 
analyzed.   
Plasma standards were prepared by serial dilution in male Sprague-Dawley rat 
plasma with K2EDTA (Bioreclamation) at 25,000, 12,500, 6,250, 3,125, 1,562, 781, 391, 
195 and 98 ng/mL AMG 517.  Plasma standards and samples were extracted with a 4x 
dilution of an internal standard (ISTD) solution (acetonitrile with 0.1 % formic acid and 
200 ng/mL AMG 8316643) and centrifuged for 20 min at 4 ˚C.   
LC/MS-MS analysis of plasma extracts was conducted on an Agilent HPLC-MSD 
Trap equipped with an APCI probe, Varian Pursuit C18, 30 x 2 mm, 5 μ column and 
ChemStation software in multiple reaction monitoring (431.1 m/z and 445.1 m/z) mode.  
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The chromatographic method was isocratic at 45 % acetonitrile in water with 0.1% 
formic acid at 0.75 mL/min.  Integration of the smoothed, extracted ion chromatogram at 
389.1 m/z was used for quantitation against the standard curve corrected with the ISTD 
concentration.  Integration of the smoothed, extracted ion chromatogram at 389.1 m/z 
with the Bruker Daltonics DataAnalysis for LC/MSD Trap software v3.3 was used for 
quantitation against the standard curve corrected with the ISTD concentration.   
Single Crystal: Attachment Energy and Morphology Calculation Methods 
Attachment energies and crystal morphologies were calculated using Dreiding 
force field4 and Ewald summation5 with Accelrys Materials Studio® v4.4 (San Diego, 
CA).  The calculated crystal morphology was determined using the attachment energy 
(AE) method.6,7  The AE method was based on atom-atom interactions within the crystal.  
The crystal morphology was determined by calculating the energy released when one 
layer of the molecular assembly was added to the growing crystal, which was 
proportional to the growth rate of the crystal face.7,8  Morphology calculations were 
compared to the morphology of crystals grown from solution to confirm consistency in 
crystal shape in order to determine molecular packing within the crystal planes. 
Statistical Calculation Methods 
Statistical differences between groups were calculated using SigmaStat for 
Windows version 3.0.1 (SPSS Inc., Chicago, IL) applying a Kruskal-Wallis9 one-way 
analysis of variance on ranks (ANOVA) followed by a multiple comparison procedure 
versus FBA (Holm-Sidak method, p value must be lower than the critical value to be 
considered significant).  Student’s t-test was used to determine statistical significance 
between two groups. 
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Results and Discussion 
Powder dissolution profiles of the four cocrystals in FaSIF over time are 
displayed in figure 5.1.  It is clear from this figure that BZA and BZD have comparable 
dissolution profiles where both cocrystals reach a similar maximum solution 
concentration of AMG 517 (Smax 30.1 and 30.5 μg/mL respectively) within 15-30 min.   
In contrast, CNA and CND have very different dissolution profiles where CND reaches 
Smax (26.5 μg/mL) at 30 min and CNA dissolves very slowly reaching a similar Smax 
(24.6 μg/mL), but not until 90 min.  The spread between the solution concentration of 






































Figure 5.1. Powder dissolution profiles to 240min of FBA and the cocrystals.   
 
Intrinsic dissolution rates (IDR) of BZA, BZD, CNA and CND (0.0012, 0.0014, 
0.0010, 0.0013 mg/cm2/min respectively) while being significantly higher than the IDR 
of FBA (0.006 mg/cm2/min, p < 0.012)), are not significantly different within the acid 
and amide pairs (BZA and BZD p = 0.184 and CNA and CND p = 0.200).  The AMG 
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517 plasma concentration over time profiles from rat pharmacokinetic investigations are 
shown in figure 5.2.  Visually this data correlates well with the powder dissolution results 
where the BZA and BZD cocrystals perform similarly while the CNA cocrystal is not 
absorbed to the same extent as the CND cocrystal maintaining a lower plasma 
concentration throughout the 24 hr study.  However no statistical difference exists 
between the DNAUC0-6hr of the acid and amide pairs (BZA and BZD p = 0.291 and CNA 
and CND p = 0.123).  Over all, the dissolution and pharmacokinetics of BZA and BZD 
are very similar while CND displays properties superior to those of CNA for 


































The crystal structure of BZD is unavailable, despite great effort to crystallize a 
suitable crystal for single crystal structure analysis; consequently the discussion as it 
relates to crystal structure will utilize only the CNA and CND acid/amide cocrystal pair 
with comparisons to FBA.  The additional hydrogen bond donor on the amide as 
compared to the carboxylic acid cocrystal former did produce two unique matrices for 
CNA and CND as shown in figure 5.3. 
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Figure 5.3. Schematic representation of hydrogen bonding in CNA and CND 
 
 
The crystal structure of CNA consists of hydrogen bonded dimers of AMG 517 
and the cocrystal former resulting in a triclinic crystal system and Pī space group.  In 
contrast to CNA the dimers of AMG 517 and cocrystal former in CND form continuous 
chains through the additional hydrogen bond from amide to amide generating a 
monoclinic crystal system and C2/c space group. 
Further in silico analysis of the crystal structures may reveal characteristics of the 
different packing arrangements which could be responsible for the difference in physical 
properties described above.  This type of analysis could be included in the form selection 
process to predict or explain physical properties of a given crystal form.  The attachment 
energy (Eatt) or the energy released per mole of layer added to a crystal face is 
proportional to the growth rate of that face.10,11  Therefore, crystal faces with a low 
absolute Eatt are the slow growing and consequently morphologically significant faces.  
These crystal faces will have the most contact with the dissolution media and will directly 
impact the rate at which dissolution occurs depending on the compatibility of the crystal 
face with the media.  The calculated Eatt of the crystal faces of FBA, CNA and CND are 
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listed in table 5.1.  Overall, the absolute attachment energies of the two faces which make 
up the most % facet area for FBA (1-10 and 001) and CNA (011 and 001) are 
approximately 4 times lower than the faces which make up the largest % facet area for 
CND (200 and 20-2). These two morphologically significant faces comprise 68.6-72.2% 
of the total surface area of all three crystals, therefore the surface properties of these faces 
are likely responsible for the bulk physical properties of the powder.    
 
Table 5.1. Calculated attachment energies for FBA, CNA and CND 
 
FBA 
face (hkl)  1 -1  0  0  0  1  1  0 -1  1  0  0  0  1  0  0  1 -1 
% total 
facet area 46.4% 22.2% 14.0% 10.9% 3.3% 3.2% 
Eatt total 
(kcal/mol) -46.4 -79.7 -89.3 -104.3 -150.7 -116.3 
CNA 
face (hkl)  0  1  1  0  0  1  1  0  1  1  1  1  1  0  0   0  1  0  1  1  0 
% total 
facet area 38.0% 34.2% 17.2% 4.1% 2.5% 2.5% 1.5% 
Eatt total 
(kcal/mol) -40.3 -42.9 -70.5 -84.1 -107.2 -70.9 -103.1 
CND 
face (hkl)  2  0  0   2  0 -2  0  0  2  1  1 -1  1  1  1  3  1 -1  1  1 -2 
% total 
facet area 37.2% 32.1% 10.7% 10.6% 7.8% 1.5% 0.1% 
Eatt total 
(kcal/mol) -169.2 -176.7 -207.4 -397.5 -400.3 -416.7 -412.7 
 
 
The calculated crystal morphologies of FBA, CNA and CND are shown in figure 5.4 
along with photomicrographs of representative crystals of the same polymorph.  The 
calculated morphologies appear to correlate well with the actual crystals.  In figure 5.5 a 
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slice of the two crystal faces with the highest % total facet area for compounds FBA, 
CNA and CND are shown.   
 
Figure 5.4. Calculated crystal morphology (top) and photomicrographs (bottom) of FBA 
(left), CNA (middle) and CND (right).   
 
The slice of the (2 0-2) face of CND indicates the presence of polar amide groups (green 
circle in figure 5.5) near the crystal face while the other morphologically significant 
crystal faces of FBA, CNA and CND contain less polar acetamide, pyrimidine or CF3 
groups.  The higher absolute attachment energies of CND and the polarity of the 
significant (2 0-2) face, which would be expected to be more hydrophilic, should provide 
a stronger interaction with the aqueous environment during the dissolution processes in 
vitro and in vivo.  This correlates well with the improved dissolution and bioavailability 




Figure 5.5. Slice through morphologically important crystal faces of FBA (top), CNA 
(middle) and CND (bottom).  Green circle highlighting the amide group on the surface of 












The AMG 517 amide cocrystals displayed unique dissolution and 
pharmacokinetic properties in only one of the two case studies above.  It is clear from the 
crystal structures of CNA and CND that the hydrogen bonding of the amide produced a 
unique packing arrangement to that of the carboxylic acid which has distinctive physical 
properties.  Without the crystal structure of BZD it is unknown if a similar difference in 
hydrogen bonding between BZD and BZA lead to the opposite result in this case.  
Although based on the rules derived by Etter12, all reliable proton donors and acceptors 
would be used in hydrogen bonding and the amide is classified as a reliable donor.  Also, 
one other AMG 517 amide cocrystal (propionamide)3 also contained the same hydrogen 
bonding pattern to that of CND.  Thus it is likely that the BZD hydrogen bonding pattern 
is at least unique to that of BZA if not the same as CND and the AMG 517 propionamide 
cocrystal.  If this is the case, the uniqueness of the hydrogen bonding and crystal packing 
did not produce distinctive dissolution rates for both amide cocrystals.  The benefit of 
expanding the list of cocrystal formers for screening of an API beyond carboxylic acids 
would likely need to be made on a case by case basis and may way more on protecting 
intellectual property than improving physical properties. 
 
References 
1. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ 2006. Pharmaceutical co-
crystals. J Pharm Sci  95(3):499-516. 
2. Schultheiss N, Newman A 2009. Pharmaceutical cocrystals and their 
physicochemical properties. Cryst Growth Des  9(6):2950-2967. 
3. Stanton MK, Tufekcic S, Morgan C, Bak A 2009. Drug substance and former 
structure property relationships in 15 diverse pharmaceutical co-crystals. Cryst 
Growth Des  9(3):1344-1352. 
 85
4. Mayo SL, Olafson BD, Goddard III WA 1990. DREIDING: A generic force field 
for molecular simulations. J Phys Chem  94:8897-8909. 
5. Koehl P 2006. Electrostatics calculations: latest methodological advances. Curr 
Opin Struct Biol  16:142-151. 
6. Hartman P, Bennema P 1980. The attachment energy as a habit controlling factor: I. 
Theoretical considerations. J Cryst Growth  49(1):145-149. 
7. Berkovitch-Yellin Z 1985. Toward an ab initio derivation of crystal morphology. J 
Am Chem Soc  107(26):8239-8253. 
8. Hartman P, Bennema P 1980. The attachment energy as a habit controlling factor: I. 
Theorectical considerations. J Cryst Growth  49(1):145-149. 
9. Kruskal WH, Wallis WA 1952. Use of ranks in one-criterion variance analysis. J 
Am Stat Assoc  47(260):583-621. 
10. Davey R, Garside J. 2000. From molecules to crystallizers. ed., New York: Oxford 
University Press, Inc. 
11. Kiang Y-H, Shi HG, Mathre DJ, Xu W, Zhang D, Panmai S 2004. Crystal structure 
and surface properties of an investigational drug-a case study. Int J Pharm  280:17-
26. 
12. Etter MC 1990. Encoding and decoding hydrogen-bond patterns of organic 




Chapter 6: Conclusions and Future Considerations 
 Dissolution testing is a vital and widely accepted in vitro tool available to the 
pharmaceutical chemist when selecting a form of a poorly soluble drug for development 
in the clinic.   Polymorphs or salts with dissolution rates similar to or less than that of the 
free form are likely not tested further unless they posses some other benefit such as 
physical stability or processability.  The same would hold true here with different 
cocrystals or polymorphs of cocrystals.  The dissolution testing would have likely led to 
selection of the top 4-6 cocrystals to continue on to in vivo studies reducing the number 
of animal studies required to reach the clinic.  As more cocrystal screening for new APIs 
is conducted and these forms are considered for development dissolution will likely be 
embedded in the form selection process as it has been for salts, polymorphs or 
formulations of an API.  Other tools utilized in conjunction with in vitro studies such as 
the in silico attachment energy calculations conducted here would be a useful addition to 
the dissolution data especially with single crystal structure determination becoming more 
accessible, with less expensive bench top X-ray diffractometors and software with more 
automated analysis. 
 Having produced a substantial library of crystal structures of AMG 517 hydrates, 
solvates, cocrystals, polymorphs of these corystals, a cocrystal-hydrate, as well as 
cocrystals of similar compounds,36 a detailed look into patterns in crystal packing and 
conformational energies is essential.  Furthermore, any insight these results may reveal 
into the physical properties such as physical stability, hygroscopicity, dissolution and 
pharmacokinetics collected thus far is warranted.   
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 The benefit of growing the list of cocrystal formers beyond carboxylic acids to 
discover a new API form is still up for debate.  While an improvement in dissolution and 
pharmacokinetics was seen here with one amide cocrystal compared to its corresponding 
acid cocrystal, there were other carboxylic acid cocrystals which performed just as well 
as the amide cocrystal.  Also, it was shown that even cocrystals which hydrogen bond 
through the same heterosynthon may result in unique crystal packing.  Although 
protecting the intellectual property of an API is clearly vital, what is the utility of a 
cocrystal produced with a cocrystal former of an unknown or questionable safety profile?  
It may be that only when no other acceptable salts, polymorphs, cocrystals or 
formulations of the API can be produced that this option would be considered.  Further 
research and publication of these alternative cocrystals is needed to elucidate the benefit 
or futility of the effort. 
Regardless of the type of cocrystal former, cocrystallization has been shown to be 
a successful process to improve the dissolution and pharmacokinetics of the poorly 
soluble API AMG 517.  While the overall linear correlation of AUC with dissolution rate 
of all sixteen AMG 517 cocrystals and the free base form A was only moderate, 
dissolution testing of the cocrystals, either powder or intrinsic, was also considered 
valuable in selecting a cocrystal form for study in pharmacokinetic investigations. 
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Chapter 7. Appendix 
 
The following is a compilation of all X-ray powder diffraction (XRPD), 
proton nuclear magnetic resonance (1H NMR), differential scanning calorimetry 
(DSC), thermal gravimetric analysis (TGA), particle size distributions, polarized light 
microscopy (PLM) and near-infrared spectroscopy (NIR) data for FBA, FBB, FBC 
and the sixteen cocrystals.  XRPD overlay is of the original powder, the solids 
isolated from powder dissolution, the pellet after intrinsic dissolution and the solids 
isolated from the formulation.  Any changes to the original form post-dissolution or in 
the formulation are noted.  Samples isolated from FaSIF may have a peak at 28.4º 
2theta due to the FaSIF component potassium chloride.  1H NMR spectra in DMSO-
d6 of the original powder.  DSC and TGA thermograms of the original powder and 
the solids isolated post-powder dissolution.  Any changes to the form are noted.  
Particle size distributions show an overlay of the original powder, the solids in FaSIF 
post powder dissolution and the solids in the formulation post dose.  Polarized light 
microscopy photos of the original powder, the solids in FaSIF post powder 
dissolution and the solids in the formulation post dose.  NIR spectra of the original 
powder in a 20mL glass vial and the compacted powder in the woods apparatus pre 
and post intrinsic dissolution.  Any changes to the original form are noted.  The glass 
vial produced a peak at 1396 nm. FBB and FBC were not included in all 



















XRPD: No changes to form observed 
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PLM: 200x original powder (left) post powder dissolution (right) 
 
 






NIR: 1899nm minor change post intrinsic dissolution 
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FBB 
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NIR: FBC 1440 and 1953nm (H2O) 
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FBC 
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NIR: FBA more unique to FBB/FBC
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1H NMR: 0.5 eq acid; 2(CH2) integrate as 1 2.2 and 1.5ppm 
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PLM: 200x original powder (left) post powder dissolution (right) 
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BZA 






























































1H NMR: 1.0 eq acid; 2(CH) 7.9ppm, CH 7.6ppm, 2(CH) 7.5ppm 
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PLM: 200x original powder (left) post powder dissolution (right) 
 
 






NIR: FBA at 2063nm post intrinsic dissolution

















BZA glass vial 
BZA pre IDR compact 
BZA post IDR compact 
 107
BZD 



























































1H NMR: 1.0 eq amide; 2(CH) 7.86ppm, CH 7.6ppm, 2(CH) 7.45ppm 
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PLM: 200x original powder (left) post powder dissolution (right) 
 
 






NIR: Minor FBA possible at 2066nm post dissolution
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1H NMR: 1.0 eq acid; 2(CH) 7.7ppm, CH 7.6ppm, 3(CH) 7.4ppm, CH 6.5 ppm 
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PLM: 200x original powder (left) post powder dissolution (right) 
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CND 



























































1H NMR: 1.0 eq amide; 2(CH) 7.6ppm, 4(CH) 7.4ppm, CH 6.5 ppm 
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PLM: 200x original powder (left) post powder dissolution (right) 
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HBA 

































































1H NMR: 0.5 eq acid; CH integrates as 0.5 7.16ppm, 6.98ppm and 6.78ppm 
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PLM: 200x original powder (left) post powder dissolution (right) 
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GUA 
































































1H NMR: 1.0 eq acid; 2(CH2) 2.2ppm, CH2 1.7ppm 
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PLM: 200x original powder (left) post powder dissolution (right) 
 
 





NIR: FBA at 2066nm post intrinsic dissolution
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1H NMR: 1.0 eq acid; CH2 3.91ppm 
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NIR: No change 
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1H NMR: 1.0 eq acid; CH 6.83 and 5.78ppm, CH2 2.16 and 1.45ppm, CH3 0.91ppm 
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NIR: No change 
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HCA 
















































































1H NMR: 1.0 eq acid; CH 3.91ppm, CH2 1.52ppm, 2(CH2) 1.3ppm, CH3 0.87ppm 
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NIR: Changes at 1901 & 2220nm post compaction
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1H NMR: 1.0 eq acid; CH 4.03ppm, CH3 1.24ppm 
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MEA 

























































1H NMR: 0.5 eq acid; 2(CH) integrate as 1 at 6.26ppm 
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NIR: No change 
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1H NMR: 0.5 eq acid; 3(CH) integrates as 0.5 at 4.26, 2.61 and 2.47ppm 
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MIA (cont.)  
 
 
NIR: FBA very minor at 2066nm post intrinsic dissolution
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1H NMR: 1.0 eq acid; CH2 3.24ppm 
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1H NMR: 1.0 eq acid; CH 7.18 and 5.79ppm, 2(CH) 6.25ppm, CH3 1.83ppm 
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NIR: FBA at 2066nm post intrinsic dissolution

















SRA glass vial 
SRA pre IDR compact 
SRA post IDR compact 
 159
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1H NMR: 0.5 eq acid; 2(CH2) integrate as 2 at 2.42ppm 
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